Branch of science
POPULARITY
30 episodes with Pharmacogenomics
10 episodes with Pharmacogenomics
9 episodes with Pharmacogenomics
9 episodes with Pharmacogenomics
3 episodes with Pharmacogenomics
4 episodes with Pharmacogenomics
3 episodes with Pharmacogenomics
9 episodes with Pharmacogenomics
4 episodes with Pharmacogenomics
7 episodes with Pharmacogenomics
5 episodes with Pharmacogenomics
3 episodes with Pharmacogenomics
4 episodes with Pharmacogenomics
2 episodes with Pharmacogenomics
3 episodes with Pharmacogenomics
2 episodes with Pharmacogenomics
2 episodes with Pharmacogenomics
3 episodes with Pharmacogenomics
Ever thought about why medications work differently for different people? In this episode of Absolute Gene-ius, we explore the exciting field of pharmacogenomics with Wendy Wang, pharmacogenetic laboratory supervisor at Children's Mercy Hospital in Kansas City. Wendy shares how genetics can influence drug metabolism, offering a glimpse into how precision medicine can revolutionize healthcare by tailoring treatments based on an individual's unique genetic makeup.At the heart of Wendy's research is CYP2D6, a cytochrome P450 enzyme responsible for metabolizing around 20% of all prescribed medications. She explains how her lab uses digital PCR to analyze copy number variations (CNV), offering a reliable and precise method to predict drug metabolism. Wendy dives into the complexities of structural variants, the role of digital PCR in enhancing assay efficiency, and why pharmacogenomics is a critical piece of the precision medicine puzzle. Her use of delightful metaphors—like comparing genetic testing to ladling soup—makes complex science both relatable and engaging.In the Career Corner, Wendy opens up about her winding path to molecular biology, which included studying classical antiquity and nearly pursuing a career in history. She emphasizes the importance of resilience in research, embracing failure as a learning opportunity, and encourages budding scientists to reach out to mentors and explore diverse interests. Plus, hear about her most embarrassing lab mishap (hint: it involves a fire alarm) and the proud moment of publishing her first, first-author paper.Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System.
Have you ever heard of pharmacogenomics? If you haven't - then you're in the right place! Pharmacogenomics talks about how our specific genes respond differently to medications that are provided to us.Join us today as our host, Dr. Lara Varden, introduces our Program Director Dr. Gabby Gutierrez on the podcast as they talk about the world of pharmacogenomics and how important it is to take this into consideration when it comes to maintaining your health. From sharing their own personal stories, to discussing the dangers of oversupplementation, this episode is sure to equip you in responding to your health before you experience any detrimental direct effects to your body.▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Keep yourself up to date on The DNA Talks Podcast! Follow our socials below:The DNA Talks Podcast Instagram https://www.instagram.com/dnatalkspodcast/▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Music: Inspiring Motivational Background by Stock-Waveshttps://www.stock-waves.com/https://protunes.net/Video Link: https://www.youtube.com/watch?v=pbwVDTn-I0o&list=PLQtpqy3zeTGB7V5lkhkfBVaiZyrysv_fG&index=5▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Music: Peaceful Corporate by Stock-Waveshttps://protunes.net/Video Link: https://www.youtube.com/watch?v=I34bTKW8ud0&list=PLQtpqy3zeTGB7V5lkhkfBVaiZyrysv_fG▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Medical Disclaimer: The information provided in this communication is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. If you think you may have a medical emergency, call your doctor or 911 immediately.
Want to break into pharmacogenomics and precision medicine? In this episode, I sit down with Dr. Josiah Allen, a precision medicine pharmacist with nearly 20 years of experience in genomics, psychiatry, and clinical research. We explore how pharmacogenomics is revolutionizing patient care, prescribing, and the role of pharmacists in the future of medicine. We cover: • How Josiah transitioned from industry to clinical practice in pharmacogenomics • The multidisciplinary approach to precision medicine at St. Elizabeth Healthcare • Why pharmacists are the ideal leaders in pharmacogenomics • The future of personalized medicine and emerging fields beyond PGx • How to successfully implement pharmacogenomics in a healthcare setting • The importance of patient empowerment, education, and shared decision-making If you're a pharmacist looking to future-proof your career and expand into precision medicine, this episode is a must-listen! Join the ElevateRx Pharmacogenomics Summit to learn how to bring Pharmacogenomics to your practice - https://elevaterx.live/ Follow Dr Josiah Allen [https://www.linkedin.com/in/allenjosiah] on LinkedIn About me:
This podcast will highlight opportunities for pharmacogenomic testing in solid organ transplant. The speakers will discuss their experiences and challenges with utilizing pharmacogenomic testing in this patient population. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
In this episode, I have a chat with Kristine Ashcraft and Burns Blaxall about how precision-based prescribing is an essential tool for every pharmacist to adopt with urgency—we talk about: • Pharmacogenomics is a simple way to improve patient outcomes – If you think pharmacogenomics (PGx) is too complex? It's actually just another tool to help you do what you already do—optimize medications for better patient outcomes. Dr. Burns Blaxall breaks it down in a way that makes sense for everyday pharmacy practice. • Real-World proof: better outcomes, fewer medication failures – Studies show that PGx can reduce adverse drug events by 30% and prevent unnecessary ER visits and hospitalizations. If you've ever wished for a way to make sure a medication works before a patient even takes the first dose, this is it. • Making PGx work in your practice (don't let perfection be the enemy of the good) – The biggest roadblocks to using PGx? Lack of awareness, integration challenges, and concerns about reimbursement. But here's the good news—pharmacists don't have to wait for a perfect system to start making an impact. Small steps can lead to big results. • Strengthening your role as a healthcare provider – PGx is a powerful way to elevate your role in patient care and get recognized as a key decision-maker in medication management. Building strong relationships with physicians and demonstrating your value in clinical decisions can open new doors for your career. • Success Stories that show PGx in action – Imagine stopping a patient from undergoing an unnecessary, high-risk procedure—just by using PGx testing. That's exactly what happened in one case shared in this episode. If you've ever felt stuck in the cycle of dispensing and reacting to medication failures, PGx offers a proactive way to make a real difference. Join the ElevateRx Pharmacogenomics Summit to learn how to bring Pharmacogenomics to your practice - https://elevaterx.live/ Follow Kristine Ashcraft on LinkedIn - https://www.linkedin.com/in/kristineashcraft/ Follow Burns Blaxall on LinkedIn - https://www.linkedin.com/in/burnsblaxall/ About me:
What if you could take control of your health and add years to your life? In this episode of Next Steps 4 Seniors: Conversations on Aging, Wendy Jones sits down with Dr. John Calado to uncover the secrets to longevity, early detection, and proactive health measures that can make all the difference.
The Future of Pharmacogenomics, State Rep Cook, & Super Culture | TWIRx Howard McLeod, PharmD Katrina Azer About the ElevateRx Event - Pharmacogenomics Virtual Summit April 12, 2025 12pm -6pm ET About the ElevateRx Event: This event is for you if you want to: bring innovation and fresh ideas to your practice elevate your career with new skills and expertise learn how precision prescribing reduces adverse events and improves patient outcomes learn step-by-step how top pharmacogenomics pharmacists are successfully implementing PGx across various settings This event is open to pharmacists worldwide, providing practical PGx implementation strategies applicable across diverse healthcare settings. Bud Cook 50th Legislative District Pennsylvania House of Representatives GO BIG & COME HOME!! Representative Cook recently spoke at the Washington County commissioners monthly meeting about his newest initiative – “Come Home…GO BIG!” The initiative highlights Southwestern Pennsylvania, which consists of Washington, Fayette, Greene, Westmoreland and Allegheny counties, as the best place in the Commonwealth to live and work. “I stood before the commissioners and asked for a committed partnership from them in pursuing this idea,” said Cook. “I want to publicly thank them for the opportunity to present Come Home…GO BIG! I look forward to potentially working with them in the months to come.” - said Rep Cook In May 2021, Cook started to ask the public “Why Not Here?” As many people had the opportunity to work from anywhere during the pandemic, he questioned why people wouldn't want to live and work in one of the tightest-knit communities in the Commonwealth. Thus, began his focus to make Southwestern Pennsylvania a home for many and a tourist destination for others. Chris Cornelison, RPh Author & CEO SolutionsRx Creator of Super Culture™ Framework In Super Culture™, Chris Cornelison outlines five steps to transform workplaces into thriving environments where employees feel energized and appreciated. Drawing from his experience, he emphasizes the importance of building a Super Culture™, retaining talent, fostering collaboration, and improving results.
Get your Deep Dive Genetic Analysis with Dr. Panzner's team! Go here and use BSFREE as your discount code for $150 off! ----Dr. Tyler Panzner is a Ph.D. scientist with a deep background in pharmacology, cancer, neuroscience, and inflammation research. His passion for how different substances affect the body has been lifelong, but about seven years ago, he found his true calling in genetics and personalized medicine. Since then, he's been on a mission to create personalized vitamin, supplement, and lifestyle protocols tailored to each individual's unique biology.His approach is all about understanding what your cells truly need and uncovering which vitamins, supplements, or foods might not be a good match for your genetic makeup. He firmly believes that by aligning your habits with your genes, not only can you feel your best every day, but you can also lower your risk for chronic diseases in the long run. His practice focuses on genetically optimizing health, helping people unlock their body's full potential to truly thrive.Dr. Panzner sees a massive lack in supplement education across all sectors of healthcare, which shows up as unnecessary suffering as people feel worse due to the wrong supplement recommendations. He is driven to educate both practitioners for their practice and consumers in the supplement aisle of the store so they can make more informed decisions regarding their or their patient's supplementation strategies.Are there any specific questions/talking points you would like to include?: Lack of supplement pharmacology education, issues with the genetics space, cell signaling model of health, (hyper) personalized medicineLinks: https://www.drtylerpanzner.com/https://www.instagram.com/drtylerpanzner/https://www.facebook.com/dr.tylerpanznerhttps://www.linkedin.com/in/tyler-panznerhttps://www.youtube.com/channel/UC38rM0QfXxr5V3Bn4D0n9jghttps://www.tiktok.com/@drtylerpanznerOur Advice!Everything in this podcast is for educational purposes only. It does not constitute the practice of medicine and we are not providing medical advice. No Physician-patient relationship is formed and anything discussed in this podcast does not represent the views of our employers. The Fine Print!All opinions expressed by the hosts or guests in this episode are solely their opinion and are not to be used as specific medical advice. The hosts, May and Tim Hindmarsh MD, BS Free MD LLC, or any affiliates thereof are not under any obligation to update or correct any information provided in this episode. The guest's statements and opinions are subject to change without notice.Thanks for joining us! You are the reason we are here. If you have questions, reach out to us at doc@bsfreemd.com or find Tim and I on Facebook and IG.Please check out our every growing website as well at bsfreemd.com (no www) GET SOCIAL WITH US!We're everywhere here: @bsfreemd
Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.
Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.
In this episode: • A Goal Setting Framework for Pharmacists - learn how a structured approach to goal-setting helped me become an internationally recognized pharmacy writer and Pharmacogenomics Academy founder. • Discover why using a physical diary proves more effective than phone apps for goal tracking, eliminating digital distractions and enhancing focus. • 5-Category Goal System - Master a comprehensive goal-setting approach that ensures balanced personal and professional development. • Quarterly Goal Breakdown Strategy - transform large objectives into manageable quarterly targets, perfect for implementing new pharmacy services like Pharmacogenomics testing or clinical programs. • Weekly and Daily Accountability System - Implement effective progress tracking through weekly reviews and daily morning manifestos, ensuring consistent goal alignment and achievement. Resources: • Download the Goal Setting Toolkit here: https://pharmxcel.kit.com/goal-setting • Subscribe to my YouTube channel and watch the episode here: https://www.youtube.com/@katrinaazer • Stay in the know about the future of pharmacy! Sign up for exclusive updates on ElevateRx, a must-attend to elevate patient care in 2025. Join the list here: https://elevaterx.kit.com/ • Book - Atomic Habits by James Clear
Episode Title: Ketamine for Cancer and Pain Management - Journal Club Host: David Rosenblum, MD Upcoming Free Webinars: 1. Exploring Innovative Mental Health Treatments which are well reimbursed Discussing Spravato, Transmagnetic Stimulation, and Ketamine Infusion, sponsored by Big Leap Health. Register! 2. Understanding Scrambler Therapy Learn about this revolutionary approach to pain management. Register! 3. Cervical Ultrasound: Anatomy and Interventional Pain Targets Sponsored by Clarius, this session will explore advanced imaging techniques. Register! Sign up for the webinars and check out our full calendar of events. Join us for this insightful episode as we explore the potential of ketamine in transforming pain management practices! Summary In today's episode, we delve into the emerging role of ketamine in managing cancer and chronic pain. Our discussion is anchored around a comprehensive review article titled "Ketamine Use for Cancer and Chronic Pain Management," published in Frontiers in Pharmacology on February 1, 2021. This review, authored by Clayton Culp, Hee Kee Kim, and Salahadin Abdi, explores ketamine's potential as an analgesic in chronic pain conditions, particularly cancer-related neuropathic pain. Key Points from the Review Article: - Mechanism of Action: Ketamine functions as an N-methyl-D-aspartate receptor antagonist, providing analgesic effects at sub-anesthetic doses. Its ability to counteract central nervous system sensitization makes it effective in opioid-induced hyperalgesia. - Clinical Efficacy: Recent studies highlight ketamine's potential to reduce pain scores and opioid consumption, offering a promising alternative for patients with refractory pain. - Safety Profile: At lower doses used for analgesia, ketamine's safety and adverse event profile are significantly improved compared to its use as an anesthetic. - Pharmacogenomics and Interactions: The article discusses how genetic variations can affect ketamine metabolism and highlights potential drug interactions that clinicians should be aware of. Reference Culp, Clayton, Hee Kee Kim, and Salahadin Abdi. "Ketamine use for cancer and chronic pain management." Frontiers in Pharmacology 11 (2021): 599721.
Episode Title: Ketamine for Cancer and Pain Management - Journal Club Host: David Rosenblum, MD Upcoming Free Webinars: 1. Exploring Innovative Mental Health Treatments which are well reimbursed Discussing Spravato, Transmagnetic Stimulation, and Ketamine Infusion, sponsored by Big Leap Health. Register! 2. Understanding Scrambler Therapy Learn about this revolutionary approach to pain management. Register! 3. Cervical Ultrasound: Anatomy and Interventional Pain Targets Sponsored by Clarius, this session will explore advanced imaging techniques. Register! Sign up for the webinars and check out our full calendar of events. Join us for this insightful episode as we explore the potential of ketamine in transforming pain management practices! Summary In today's episode, we delve into the emerging role of ketamine in managing cancer and chronic pain. Our discussion is anchored around a comprehensive review article titled "Ketamine Use for Cancer and Chronic Pain Management," published in Frontiers in Pharmacology on February 1, 2021. This review, authored by Clayton Culp, Hee Kee Kim, and Salahadin Abdi, explores ketamine's potential as an analgesic in chronic pain conditions, particularly cancer-related neuropathic pain. Key Points from the Review Article: - Mechanism of Action: Ketamine functions as an N-methyl-D-aspartate receptor antagonist, providing analgesic effects at sub-anesthetic doses. Its ability to counteract central nervous system sensitization makes it effective in opioid-induced hyperalgesia. - Clinical Efficacy: Recent studies highlight ketamine's potential to reduce pain scores and opioid consumption, offering a promising alternative for patients with refractory pain. - Safety Profile: At lower doses used for analgesia, ketamine's safety and adverse event profile are significantly improved compared to its use as an anesthetic. - Pharmacogenomics and Interactions: The article discusses how genetic variations can affect ketamine metabolism and highlights potential drug interactions that clinicians should be aware of. Reference Culp, Clayton, Hee Kee Kim, and Salahadin Abdi. "Ketamine use for cancer and chronic pain management." Frontiers in Pharmacology 11 (2021): 599721.
Episode Title: Ketamine for Cancer and Pain Management - Journal Club Host: David Rosenblum, MD Upcoming Free Webinars: 1. Exploring Innovative Mental Health Treatments which are well reimbursed Discussing Spravato, Transmagnetic Stimulation, and Ketamine Infusion, sponsored by Big Leap Health. Register! 2. Understanding Scrambler Therapy Learn about this revolutionary approach to pain management. Register! 3. Cervical Ultrasound: Anatomy and Interventional Pain Targets Sponsored by Clarius, this session will explore advanced imaging techniques. Register! Sign up for the webinars and check out our full calendar of events. Join us for this insightful episode as we explore the potential of ketamine in transforming pain management practices! Summary In today's episode, we delve into the emerging role of ketamine in managing cancer and chronic pain. Our discussion is anchored around a comprehensive review article titled "Ketamine Use for Cancer and Chronic Pain Management," published in Frontiers in Pharmacology on February 1, 2021. This review, authored by Clayton Culp, Hee Kee Kim, and Salahadin Abdi, explores ketamine's potential as an analgesic in chronic pain conditions, particularly cancer-related neuropathic pain. Key Points from the Review Article: - Mechanism of Action: Ketamine functions as an N-methyl-D-aspartate receptor antagonist, providing analgesic effects at sub-anesthetic doses. Its ability to counteract central nervous system sensitization makes it effective in opioid-induced hyperalgesia. - Clinical Efficacy: Recent studies highlight ketamine's potential to reduce pain scores and opioid consumption, offering a promising alternative for patients with refractory pain. - Safety Profile: At lower doses used for analgesia, ketamine's safety and adverse event profile are significantly improved compared to its use as an anesthetic. - Pharmacogenomics and Interactions: The article discusses how genetic variations can affect ketamine metabolism and highlights potential drug interactions that clinicians should be aware of. Reference Culp, Clayton, Hee Kee Kim, and Salahadin Abdi. "Ketamine use for cancer and chronic pain management." Frontiers in Pharmacology 11 (2021): 599721.
Leanne Williams is an expert in depression. The first thing that she wants the world to know is that depression is not some sort of character flaw, but a real illness with symptoms that can impair one's ability to function day to day. The past decade has seen remarkable advances, she says, as functional MRI has opened new avenues of understanding depression's mechanisms and its treatments. These are hopeful times for the science of depression, Williams tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Leanne WilliamsConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Leanne Williams, a professor of Psychiatry and Behavioral Science at Stanford University.(00:02:13) What Is Depression?Distinguishing clinical depression from everyday sadness.(00:04:02) Current Depression Treatment ChallengesThe trial-and-error of traditional depression treatments and their extended timelines.(00:06:46) Brain Mapping and Circuit DysfunctionsAdvanced imaging techniques and their role in understanding depression.(00:09:33) Diagnosing with Brain ImagingHow brain imaging can complement traditional diagnostic methods in psychiatry.(00:10:52) Depression BiotypesIdentifying six distinct biotypes of depression through brain imaging(00:14:41) Biotypes and Personalized TreatmentsHow biotypes allow for targeted therapies and improve treatment outcomes.(00:19:33) AI in Depression TreatmentUsing AI to refine biotypes and predict treatment outcomes with greater accuracy.(00:22:45) Psychedelics in Depression TreatmentThe potential for psychedelic drugs to target specific biotypes of depression.(00:24:16) Expanding the Biotypes FrameworkIntegrating multimodal approaches into the biotype framework.(00:27:59) Reducing Stigma in DepressionHow showing patients their brain imaging results reduces self-blame and stigma.(00:30:08) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook
This Week in Pharmacy – December 13, 2024 Digital Health & Community Pharmacy: Best Buy Health's Three-Pronged Strategy | TWIRx Join us for another exciting episode of This Week in Pharmacy (TWIRx) with host Todd Eury, featuring insightful discussions on the latest trends shaping pharmacy and healthcare. Special Guests: Brian Urban – Director of Strategy at Best Buy Health Ashton S. Maaraba, J.D. – President of Digital Health, iCare+ Topics Discussed: The Future of Digital Health & Community Pharmacy Best Buy Health's Three-Pronged Strategy: Consumer Health Products: Empowering healthier lifestyles through innovative devices. Emergency Response Services: Device-based solutions for active aging adults, ensuring safety and independence. Virtual Care Offerings: Connecting patients and physicians for seamless healthcare experiences. Ashton S. Maaraba shares insights on digital transformation in pharmacy, the integration of health tech, and how iCare+ is redefining patient engagement and care delivery. TWIRx News with Special Co-Host Dr. Ryan Paul Legislative Updates: U.S. Senators and State Representatives propose a bill to ban joint ownership of PBMs and pharmacies. What does this mean for the pharmacy landscape? Todd and Dr. Ryan Paul discuss the implications and potential impact on healthcare access and pricing. Pharmacogenomics in Specialty Pharmacy: Exploring the rise of pharmacogenomics and how it is reshaping personalized medicine. Opportunities for independent community pharmacies to offer cash-based pharmacogenomics services as a new revenue stream. Sponsors: IPC (Independent Pharmacy Cooperative): Empowering independent pharmacies with solutions to enhance profitability and patient care. Happier at Home: Supporting pharmacists in delivering home-based healthcare services for seniors and disabled individuals. Call to Action: Subscribe to This Week in Pharmacy on your favorite podcast platform and leave us a review! Follow us on social media for updates, behind-the-scenes content, and more industry insights. Learn more about Best Buy Health's innovative approach to digital health and iCare+'s initiatives at their respective websites. Stay informed and inspired with This Week in Pharmacy! Follow the Pharmacy Podcast Network: Website: PharmacyPodcast.com Twitter: @PharmacyPodcast LinkedIn: Pharmacy Podcast Network #PharmacyPodcast #DigitalHealth #CommunityPharmacy #Pharmacogenomics #PBMReform
In this exciting episode of the Pediatric Pharmacist Review Podcast, we're diving into the fascinating world of pharmacogenomics and its transformative impact on pediatric care. Our special guest is Dr. Kelly E. Caudle, Pharm.D., Ph.D., FCCP, an Associate Member in the Department of Pharmacy and Pharmaceutical Sciences at St. Jude Children's Research Hospital. Dr. Caudle brings a wealth of expertise to the discussion, with over a decade of experience in pharmacogenomics implementation. As the Director of the NIH-funded Clinical Pharmacogenetics Implementation Consortium (CPIC), she oversees groundbreaking work in translating genetic test results into actionable prescribing decisions. With CPIC publishing 28 gene-based clinical guidelines covering 29 genes and over 150 drugs, Dr. Caudle's leadership is reshaping personalized medicine for children worldwide. Tune in as we explore how pharmacogenomics is enabling tailored treatments for pediatric patients, improving medication efficacy, and minimizing adverse effects. Dr. Caudle also shares insights into her work at St. Jude Children's Research Hospital and offers a glimpse into the future of personalized pediatric care. Key Takeaways: What pharmacogenomics is and why it matters for pediatric medicine. How CPIC guidelines are helping clinicians make data-driven prescribing decisions. The role of genetic testing in improving medication safety and outcomes for children. Dr. Caudle's journey in leading pharmacogenomics research and clinical implementation. Guest Bio: Dr. Kelly E. Caudle is a leading expert in pharmacogenomics, with over 100 publications and abstracts to her name. Her work has advanced the clinical implementation of pharmacogenetics at St. Jude Children's Research Hospital and beyond. As a passionate researcher and educator, she has inspired countless professionals through her national and international presentations.
Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Dr. Jeremy Stuart, Chief Scientific Officer and laboratory director for Precision Genetics, discuss pharmacists value as employees in clinical pharmacogenomics testing laboratories. Having employed pharmacists in his laboratories, Dr. Stuart will provide his first-hand examples to illustrate how pharmacists have benefited his laboratories. Dr. Winslow and Dr. Sarrami will also share their real-world experiences working for clinical pharmacogenomics laboratories to help the laboratory achieve its goals. This episode is a must listen for laboratories who are vested in their pharmacogenomics testing's financial success. After listening to this episode, the learner will be able to describe responsibilities and roles in pharmacogenomics pharmacists fulfill in clinical labs, name specific real-world examples that illustrate pharmacists' contributions to pharmacogenomics in the clinical laboratory, and name education, training, and work experiences that prepare pharmacists to assume advanced practice roles in clinical laboratories. Dr. Jeremy Stuart has extensive experience in the life science industry. He specializes in commercial operations, technology development and transfer, manufacturing design, and validation of laboratory developed tests (LDTs). He currently serves as the Chief Scientific Officer for Precision Genetics and serves as their Laboratory Director. Dr. Stuart was part of the senior management team that completed a management buyout of Lab21 Inc. to form Selah Genomics and the subsequent sale of Selah to EKF. Dr. Stuart led the development and validation of all of Selah's molecular assays and oversaw their clinical studies. Dr. Stuart was also a member of the Agencourt Personal Genomics team, where he co-developed the SOLiD next-generation sequencing technology that was subsequently acquired by Applied Biosystems. Before entering industry, Dr. Stuart completed his postdoctoral work at the the Harvard School of Public Health, earned his master's degree in Toxicology from the University of Minnesota, and his doctorate in Genetics & Complex Diseases from Harvard University. As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University. Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.
Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Dr. Jeremy Stuart, Chief Scientific Officer and laboratory director for Precision Genetics, discuss pharmacists value as employees in clinical pharmacogenomics testing laboratories. Having employed pharmacists in his laboratories, Dr. Stuart will provide his first-hand examples to illustrate how pharmacists have benefited his laboratories. Dr. Winslow and Dr. Sarrami will also share their real-world experiences working for clinical pharmacogenomics laboratories to help the laboratory achieve its goals. This episode is a must listen for laboratories who are vested in their pharmacogenomics testing's financial success. After listening to this episode, the learner will be able to describe responsibilities and roles in pharmacogenomics pharmacists fulfill in clinical labs, name specific real-world examples that illustrate pharmacists' contributions to pharmacogenomics in the clinical laboratory, and name education, training, and work experiences that prepare pharmacists to assume advanced practice roles in clinical laboratories. Dr. Jeremy Stuart has extensive experience in the life science industry. He specializes in commercial operations, technology development and transfer, manufacturing design, and validation of laboratory developed tests (LDTs). He currently serves as the Chief Scientific Officer for Precision Genetics and serves as their Laboratory Director. Dr. Stuart was part of the senior management team that completed a management buyout of Lab21 Inc. to form Selah Genomics and the subsequent sale of Selah to EKF. Dr. Stuart led the development and validation of all of Selah's molecular assays and oversaw their clinical studies. Dr. Stuart was also a member of the Agencourt Personal Genomics team, where he co-developed the SOLiD next-generation sequencing technology that was subsequently acquired by Applied Biosystems. Before entering industry, Dr. Stuart completed his postdoctoral work at the the Harvard School of Public Health, earned his master's degree in Toxicology from the University of Minnesota, and his doctorate in Genetics & Complex Diseases from Harvard University. As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University. Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.
Emily Doycich sits down with VA pharmacists Susan Duquaine and Abbey Loy to discuss best practices for implementing a pharmacogenomics program withing a health system including clinical and operational considerations along with how they addressed barriers and keep up with this ever-evolving area of pharmacy practice. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
Can you know what medicine will work for you—before you take it? The field of pharmacogenomics seeks to understand just that. Pharmacogenomics explores how our genes can influence our response to medications, and how genetic testing can help doctors optimize medical treatment for certain health conditions. Tune in to episode 211 of our Eat Move Think podcast to hear Jessica Gu, Medcan's Clinical Director of Genetics, explain: What pharmacogenomics is How pharmacogenomics works, including how your genes can influence medication effectiveness and the side effects you may experience Which conditions pharmacogenomics is most useful for, including mental health, cardiovascular conditions, and more. How pharmacogenomic testing works and what to expect during the testing process What You Can Do To find out if you are a good candidate for pharmacogenomic testing, speak to your primary care physician. You can also contact Medcan to request a consultation with one of our genetic counsellors at medcan.com/genetics. If you would like more information on working with one of our primary care physicians toward optimal health, visit medcan.com/care.
Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over eleven years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Kentucky Teachers' Retirement System, GenXys, and Thermo Fisher Scientific. A sought-after pharmacogenomics subject matter expert, Dr. Winslow, has authored PGx payer databases and billing and coding algorithms and served Mintz Law as the expert medical necessity reviewer of Medicare PGx claims. She is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders. Dr. Winslow is an Advanced Pharmacy Practice Experience preceptor for Manchester University School of Pharmacy PharmD/Masters in PGx students and a registered trainer for the University of Pittsburgh's Test2Learn (TM) Community PGx Certificate Program. Dr. Winslow is a member of the Clinical Pharmacogenetics Implementation Consortium, the NCPDP PGx Task Force, and the Get the Medications Right Institute. In 2021, Welp Magazine recognized Dr. Winslow's podcast, the PGx for Pharmacists Podcast, as the world's ninth most listened-to genetics podcast. Her podcast shares the top 20 most listened-to genomics podcast list with genomics podcasts created by such notable podcasters as the National Cancer Institute and the American Heart Association. The Pharmacy Podcast Network recognized Dr. Winslow in 2021 as a Top 50 pharmacy influencer. Entities frequently recruit Dr. Winslow to present PGx topics. She has presented at conferences for the National Association of Boards of Pharmacy, the National Association of Specialty Pharmacy, the Inovalon Customer Congress, and the Association for Molecular Pathology and on the Labroots' and Precision Medicine Institute's platforms. Dr. Winslow earned her Bachelor of Science in Biology and Doctor of Clinical Pharmacy degrees from Campbell University. Lexi Wensel is a 2024 Manchester University School of Pharmacy graduate where she earned her Doctorate in Pharmacy and Masters in Pharmacogenomics. When this episode was recorded in April 2024, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. While studying to become a pharmacist, Lexi gained practical clinical pharmacy experience while working as a pharmacy intern at both Meijer pharmacy and Marion Health Hospital. Beyond her academic and professional endeavors, Lexi is deeply committed to giving back to the community. She serves as a board member for an organization called Guatemala Family Development where she contributed to initiatives aimed at improving healthcare access and promoting wellness in underserved communities. At the time this episode was recorded, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. Dr. Mary Weissman is a clinical pharmacogenomics specialist and inGENEious RX Incorporated consultant. Since earning her Doctor of Pharmacy degree from Arnold and Marie Schwartz College of Pharmacy and completing a two-year pharmacogenomics fellowship in a clinical laboratory's medical affairs department, Dr. Weissman has applied her pharmacogenomics expertise in clinical diagnostic laboratories. At those laboratories, she has scientifically, and clinically supported pharmacogenomics stakeholders to increase clinical pharmacogenomics implementation into clinical settings. Holding titles such as clinical scientist, she has authored and developed medical content to educate healthcare providers and patients about pharmacogenomics and authored clinical decision support tools prescribers use to leverage pharmacogenomic insights in medication therapy management. Through educational trainings, white papers, presentations, and webinars, she has clarified pharmacogenomics' complexities and helped move pharmacogenomics toward a standard of care.
Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over eleven years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Kentucky Teachers' Retirement System, GenXys, and Thermo Fisher Scientific. A sought-after pharmacogenomics subject matter expert, Dr. Winslow, has authored PGx payer databases and billing and coding algorithms and served Mintz Law as the expert medical necessity reviewer of Medicare PGx claims. She is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders. Dr. Winslow is an Advanced Pharmacy Practice Experience preceptor for Manchester University School of Pharmacy PharmD/Masters in PGx students and a registered trainer for the University of Pittsburgh's Test2Learn (TM) Community PGx Certificate Program. Dr. Winslow is a member of the Clinical Pharmacogenetics Implementation Consortium, the NCPDP PGx Task Force, and the Get the Medications Right Institute. In 2021, Welp Magazine recognized Dr. Winslow's podcast, the PGx for Pharmacists Podcast, as the world's ninth most listened-to genetics podcast. Her podcast shares the top 20 most listened-to genomics podcast list with genomics podcasts created by such notable podcasters as the National Cancer Institute and the American Heart Association. The Pharmacy Podcast Network recognized Dr. Winslow in 2021 as a Top 50 pharmacy influencer. Entities frequently recruit Dr. Winslow to present PGx topics. She has presented at conferences for the National Association of Boards of Pharmacy, the National Association of Specialty Pharmacy, the Inovalon Customer Congress, and the Association for Molecular Pathology and on the Labroots' and Precision Medicine Institute's platforms. Dr. Winslow earned her Bachelor of Science in Biology and Doctor of Clinical Pharmacy degrees from Campbell University. Lexi Wensel is a 2024 Manchester University School of Pharmacy graduate where she earned her Doctorate in Pharmacy and Masters in Pharmacogenomics. When this episode was recorded in April 2024, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. While studying to become a pharmacist, Lexi gained practical clinical pharmacy experience while working as a pharmacy intern at both Meijer pharmacy and Marion Health Hospital. Beyond her academic and professional endeavors, Lexi is deeply committed to giving back to the community. She serves as a board member for an organization called Guatemala Family Development where she contributed to initiatives aimed at improving healthcare access and promoting wellness in underserved communities. At the time this episode was recorded, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. Dr. Mary Weissman is a clinical pharmacogenomics specialist and inGENEious RX Incorporated consultant. Since earning her Doctor of Pharmacy degree from Arnold and Marie Schwartz College of Pharmacy and completing a two-year pharmacogenomics fellowship in a clinical laboratory's medical affairs department, Dr. Weissman has applied her pharmacogenomics expertise in clinical diagnostic laboratories. At those laboratories, she has scientifically, and clinically supported pharmacogenomics stakeholders to increase clinical pharmacogenomics implementation into clinical settings. Holding titles such as clinical scientist, she has authored and developed medical content to educate healthcare providers and patients about pharmacogenomics and authored clinical decision support tools prescribers use to leverage pharmacogenomic insights in medication therapy management. Through educational trainings, white papers, presentations, and webinars, she has clarified pharmacogenomics' complexities and helped move pharmacogenomics toward a standard of care.
Send us a textReady to expand your pharmacy? Make sure you have a solid financial foundation. Schedule an Rx Assessment todayPharmacy Owners...It's time to elevate your pharmacy and reimagine clinical care with the power of collaboration.In this episode of The Bottom Line Pharmacy Podcast, Scotty Sykes, CPA, CFP and Bonnie Bond, CPA sit down with Amina Abubakar, PharmD, Founder and CEO of Avant Pharmacy and Wellness Center to discuss:Expanding Services Through Collaborative Clinical CareGaining and Building Trust with Local ProvidersImproving Patient OutcomesAnd More!Did you like this episode? Stay up to date on new episodes by liking and subscribing!Read and follow along with this episode at the show transcript(insert transcript link) More about our guest:Amina Abubakar graduated from the Philadelphia College of Pharmacy University of the Sciences in 2005. She is the owner and manager of Avant Pharmacy & Wellness Center formerly known as Rx Clinic Pharmacy in Charlotte, NC, and the founder of the Avant Institute.She is an internationally recognized award-winning clinical pharmacist, Certified HIV Specialty Pharmacist, a preceptor to UNC Chapel Hill residents and students from several schools of pharmacy. Recently, Amina was bestowed the honor by the National Community Pharmacists Association as 2020's Independent Pharmacist of the Year and also received the 2020 Bowl of Hygeia from the North Carolina Association of Pharmacists for outstanding service to the community.She has fostered an environment that showcases the impact of community pharmacists on patient care by collaborating with medical providers and expanding pharmacist-led clinical services in her community. Her desire to help others advance the pharmacy profession inspired her to found the Avant Institute to offer training to pharmacies across the country on the practical application of clinical pharmacy services through developing sustainable physician collaborations.Currently, she shares her passion for pharmacy advancements with pharmacists, patients and policy makers all over the country through Pharmacogenomics. She was invited to the White House Office of Science and Technology Policy and to the FDA to discuss the role of pharmacists in pharmacogenomics.Amina Abubakar LinkedInAvant Pharmacy and Wellness WebsiteAvant Pharmacy and Wellness FacebookAvant Pharmacy and Wellness LinkedInStay connected with us on social media: FacebookTwitterLinkedIn Scotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP Twitter Bonnie Bond – CPA LinkedIn Bonnie Bond – CPA Twitter More Resources on this Topic:Blog - 3 Accounting Essentials for 2024Podcast - The Fundamentals of Independent Pharmacy Accounting
A nice editorial succinctly summarizes a framework for thinking about how to incorporate anthracyclines into the treatment of early stage breast cancer patients. Anthracyclines in Early Breast Cancer: The Long Goodbye -https://doi.org/10.1200/JCO-24-01916 10-year Outcomes of READ trial: https://doi.org/10.1200/JCO.24.00836 Bonus - Practical Guide for Testing for Pharmacogenomics: https://doi.org/10.1200/OP.24.00191
In this episode, we continue the discussion from last week as we tackled the death of Matthew Perry and the Genetics of Addiction. Our hosts are joined by Dr. Tiffany M. Smith who is an Integrative and Functional Psychiatric Nurse Practitioner. She is the founder of Aroma Functional Nutrition Psychiatry. Dr. Smith is on a mission to empower individuals and organizations to achieve optimal mental and physical well-being through personalized, integrative, and functional care combined with holistic wellness solutions. We are also joined by Tahir Khorasanee B.A. (Hon.), LL.B., LL.M. who is the Vice President of the Employment Lawyers Association of Ontario and regularly advises employers and employees in all manner of employment, labor and human rights issues.Join us as we dive deeper into the circumstances surrounding Matthew Perry's death - both on the legal side and the importance of medical history. We also take a look into how we can help and prevent overdose of these prescription drugs if someone we know has been taking them, and how proper testing can make all the difference.If you wish to learn more from Dr. Smith, you may do so through the following channels.Instagram: @dr.tiffanymsmith Facebook: Aroma Functional Nutrition Psychiatry, LLC | Las Vegas NV | Facebook Website: Dr. Tiffany M Smith (afnpsych.com) If you wish to learn more from Tahir, you may take a look into the website of their firm: https://steinbergsllp.com/tahir-khorasanee/▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Keep yourself up to date on The DNA Talks Podcast! Follow our socials below:The DNA Talks Podcast Instagram https://www.instagram.com/dnatalkspodcast/Bryce Wylde's Official Instagram Page https://www.instagram.com/wyldeonhealth/▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Music: Inspiring Motivational Background by Stock-Waveshttps://www.stock-waves.com/https://protunes.net/Video Link: https://www.youtube.com/watch?v=pbwVDTn-I0o&list=PLQtpqy3zeTGB7V5lkhkfBVaiZyrysv_fG&index=5▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Music: Peaceful Corporate by Stock-Waveshttps://protunes.net/Video Link: https://www.youtube.com/watch?v=I34bTKW8ud0&list=PLQtpqy3zeTGB7V5lkhkfBVaiZyrysv_fG▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Medical Disclaimer: The information provided in this communication is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. If you think you may have a medical emergency, call your doctor or 911 immediately.
Imagine knowing how your body will respond to a medication before you even take it! In this episode, Harsh Thakkar interviews Sarah Rogers, co-founder and president of the American Society of Pharmacovigilance (ASP) and an Assistant Professor at Texas A&M. Together, they dive deep into the fascinating world of pharmacogenomics—how your genetic makeup affects your response to medications. They discuss the challenges of pharmacogenomic testing, real-world examples of adverse drug reactions, and the future of personalized medicine. Chapters:00:00 - Intro00:16 - Breaking Down Pharmacogenomics01:39 - Guest Introduction: Sarah Rogers 02:18 - Explaining Pharmacogenomics to a Child03:24 - Sarah's Start in Pharmacogenomics 04:54 - The Power of Pharmacogenomics07:00 - Pharmacogenomics Clinic at Texas A&M 09:02 - Challenges of Standardizing PGX Testing11:14 - The Ideal Pharmacogenomics Workflow13:39 - Real-World Example of PGX in Action15:44 - Importance of Integrating PGX into EHR 20:24 - AI and Digital Twins in Pharmacogenomics21:52 - Lessons Learned in Pharmacogenomics24:46 - Looking to the Future of Personalized Medicine28:18 - Final Takeaway 30:22 - Outro Connect with Sarah Rogers:- LinkedIn: (https://www.linkedin.com/company/american-society-of-pharmacovigilance) - STRIPE Initiative LinkedIn: (https://www.linkedin.com/company/stripe-pharmacogenomics) - Twitter: (https://twitter.com/amsocietypharm) - Newsletter signup for the American Society of Pharmacovigilance: https://www.stopadr.org/Here are links for some of the information that I mentioned during our meeting:- STRIPE Annual Meeting and Consensus Workshop - (https://www.usp.org/node/289416) - Collaborative Communities: Addressing Health Care Challenges Together(https://www.fda.gov/about-fda/cdrh-strategic-priorities-and-updates/collaborative-communities-addressing-health-care-challenges-together)- Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community - (https://stopadr.org/stripe)- Texas A&M Interprofessional Pharmacogenomics (IPGx) Clinic - (https://ibt.tamu.edu/cores/Texas%20ClinicoGenomics/Texas%20ClinicoGenomics.html)- National Action Plan for Adverse Drug Event Prevention - (https://health.gov/sites/default/files/2019-09/ADE-Action-Plan-508c.pdf)- Figure showing Stakeholders Involved in the Lifecycle of a Pharmacogenomics Test(https://www.nature.com/articles/s41397-024-00345-y/figures/1)- Subscribe to our podcast for more insights on life sciences:
Tailoring cannabis and CBD to your DNA has the potential to transform your health. Len May, CEO of EndoDNA, shares his groundbreaking journey from using cannabis to manage ADD to becoming a global authority on medicinal cannabis and the endocannabinoid system. He explains how understanding your unique genetic makeup can help you avoid negative side effects and get the most out of your cannabis experience.This episode delivers a deep dive into personalized medicine, revealing how cannabis can be a tool to enhance longevity and improve quality of life. Whether you're experienced with cannabis or just starting, Len's insights offer a fresh perspective on using DNA to make cannabis work better for you.Find Len May Online Here:Instagram: @lenmaydnaFacebook: Len MayYouTube: Len May DNABook: Making Cannabis PersonalPodcast: Everything is PersonalWebsite: EndoDNA.comFind The Pain Game Podcast Online Here:Website: thepaingamepodcast.comInstagram: @thepaingamepodcastEpisode Highlights:(00:00) Introduction to Chronic Pain and Cannabis(02:31) Personalized Medicine and Cannabis(06:45) Understanding the Endocannabinoid System(10:58) The Role of DNA in Cannabis Use(19:15) The Process of DNA Testing for Cannabis(28:53) Precision Wellness and Healthcare Collaboration(36:32) Empowering Patients Through Knowledge
Are you prioritizing yourself, or are you stuck in people-pleasing and overachievement? In this episode, Lesley Logan interviews Whitney Prude, a Board Certified Clinical Pharmacist and wellness coach, who shares her transformative journey from career burnout to self-love. Whitney reveals how women can stop the cycle of self-neglect, find their true worth, and make self-love a priority. Tune in for a conversation about letting go of people-pleasing, shifting from external to internal motivation, and leaning into the discomfort for lasting change.If you have any questions about this episode or want to get some of the resources we mentioned, head over to LesleyLogan.co/podcast. If you have any comments or questions about the Be It pod shoot us a message at beit@lesleylogan.co. And as always, if you're enjoying the show please share it with someone who you think would enjoy it as well. It is your continued support that will help us continue to help others. Thank you so much! Never miss another show by subscribing at LesleyLogan.co/subscribe.In this episode you will learn about:Whitney's transition from pharmacist to wellness coach.How her autoimmune disease forced a career shift.The harmful effects of people-pleasing and overachievement.How to recognize early signs of burnout before it's too late.The importance of prioritizing self-love and emotional care.Why leaning into discomfort is key to personal progress.How to shift your motivation from external validation to internal fulfillment.Episode References/Links:Whitney Prude InstagramWhitney Prude WebsiteFemGevityDr Mindy PelzGuest Bio:Whitney Prude is a practicing Board Certified Clinical Pharmacist (PharmD, BCPS), as well as a Mayo Clinic Certified Wellness Coach and Nationally Certified Health and Wellness Coach (NBC-HWC). She earned her Doctorate of Pharmacy Degree at Roseman University of Health Sciences in South Jordan, Utah, and completed a Post-Graduate Residency (PGY1) at the University of New Mexico Hospitals in Albuquerque, New Mexico. She obtained her coaching certification through the Mayo Clinic Wellness Coaching Program, which is certified by the National Board of Health and Wellness Coaching. Additionally, she is certified in Medication Therapy Management and Pharmacogenomics. She currently works as an inpatient clinical pharmacist at Mayo Clinic in Rochester, Minnesota, where she has been for 7 years. She is also a public speaker, entrepreneur, and CEO of Whole & Happy Living, a health and wellness company offering coaching, education, and medication review. Her true passion lies in helping others transform their health so they can live their absolute best life possible. If you enjoyed this episode, make sure and give us a five star rating and leave us a review on iTunes, Podcast Addict, Podchaser or Castbox. DEALS! Check out all our Preferred Vendors & Special Deals from Clair Sparrow, Sensate, Lyfefuel BeeKeeper's Naturals, Sauna Space, HigherDose, AG1 and ToeSox Be in the know with all the workshops at OPCBe It Till You See It Podcast SurveyBe a part of Lesley's Pilates MentorshipFREE Ditching Busy Webinar Resources:Watch the Be It Till You See It podcast on YouTube!Lesley Logan websiteBe It Till You See It PodcastOnline Pilates Classes by Lesley LoganOnline Pilates Classes by Lesley Logan on YouTubeProfitable Pilates Follow Us on Social Media:InstagramFacebookLinkedIn Episode Transcript:Whitney Prude 0:00 You need to be at number one. If you want to show up for your kids, if you want to show up for your husband, if you want to be here in 20 years when you have grandkids and you want to see their kids and whatever, you want all of that stuff to happen, then you've got to start putting yourself at number one.Lesley Logan 0:15 Welcome to the Be It Till You See It podcast where we talk about taking messy action, knowing that perfect is boring. I'm Lesley Logan, Pilates instructor and fitness business coach. I've trained thousands of people around the world and the number one thing I see stopping people from achieving anything is self-doubt. My friends, action brings clarity and it's the antidote to fear. Each week, my guest will bring bold, executable, intrinsic and targeted steps that you can use to put yourself first and Be It Till You See It. It's a practice, not a perfect. Let's get started. Lesley Logan 0:56 All right, Be It babe. Okay. I'm excited. I am so excited for you to listen to this conversation. It was more than I ever expected. So when I met today's guest, I was like, yeah, I want to talk about this. This is great. This is exactly what I want to talk about. And just my schedule is kind of crazy so I couldn't talk to her until today. And today–the day that we're recording it–is the three-year anniversary of the podcast, and so super, just so exciting, and to be able to have this conversations, honest conversation that is really for the ladies who are listening, but if you are a male listening, thank you. And there are women listening in your life, there are women in your lives, and I think it's really important that you hear this and then also you share this with them. So we are going to talk a lot about self love and achieving and also people-pleasing. And today's guest is really just an expert in really helping you work internally on yourself. But a lot of times people work with her because of external stuff. So it's just great. It's amazing. Get ready to hit rewind a couple of times. I remember when Oprah goes, that's a tweet. Tweet, when Twitter was new, she's like, that's a tweet. Tweet. Like, I just want to go this is like, hold on. I just need, like, there's a Be It mic drop moment. We'll have to come up–send in your suggestions for these things. But I just really, absolutely love today's interview, and I cannot wait for you to hear our guest's amazingness. So here is Whitney Prude. Lesley Logan 2:17 All right, Be It, babe. I'm really excited to have this conversation today. I've met Whitney, our guest today, a while back, and I just really love the mission she's on and her tips and advice that she has, so I'm excited to share that with you. Whitney Prude is our guest. Can you tell everyone who you are and what you rock at? Whitney Prude 2:31 Well, thank you, first of all, for having me. Like you said, I'm Whitney Prude. I am a Board Certified Clinical Pharmacist and I'm also a certified health and wellness coach and a certified nutrition coach. So what do I rock at? Well, I try to crush it at all of those things where I have certifications. Lesley Logan 2:51 Should I be calling you Dr. Prude? Am I supposed to be calling you– or Dr. Whitney? Whitney Prude 2:57 I don't know. It feels a little uncomfortable to me. I don't need to be called doctor. I mean, I am a doctor, but it feels kind of weird, because medical doctors are called doctor and so it's always like, just call me Whitney. I don't want to, you know, but yes, I do have a doctorate degree. I'm a pharmacist, but I'm not currently working as a pharmacist. I've kind of stepped away, and I'm working full-time in my business, and it's been a fun journey.Lesley Logan 3:20 That's amazing. Okay, I just want to like shout out. And maybe I'm ignorant, but you worked at the Mayo Clinic for many years. Like, don't we consider the Mayo Clinic is, like, the top the best of the best, right? Like, this is where everyone goes. Like, yes, don't be so humble. Like you, you, you've done some amazing work in the medical field. And then the fact that I love that you mentioned certified against the health and wellness and the nutrition, because so many people, they have certificates, not necessarily certification. So what drew you to in the being a pharmacist to also then going after these other educations and these other areas of expertise?Whitney Prude 3:58 Yeah, good question. I never intended on doing what I'm doing right now. That was not it wasn't in my plan. I never imagined that I would be a business owner. I never imagined that I would be a coach. It wasn't in my plan. My dream was to be a pharmacist. I worked my whole life to be a pharmacist. I had decided, since I was in high school, to be a pharmacist, and I became a pharmacist. I worked in pharmacy for about eight years before I stepped away to do my own business. But that was my dream, that was my goal, and life had different things in mind for me. I don't know if you want to dive into my story. I'm happy to if you'd like me to, but.Lesley Logan 4:34 Yes. If you're willing to share it I love our listeners to hear first of all, to be honest that it wasn't in your plan. Sometimes I'm like, do we need to have plans? But then yes, because, like, a plan is a road map, and if you're willing to allow yourself to go on an adventure, then you'll eventually get to somewhere better than what you could have imagined from your first plan. So, but I would love if you're willing to share. Whitney Prude 4:56 Yeah, 100%. I think it is important to have a roadmap to think, you know, to have a goal is something that you want to get to, a dream, whatever, right? And you can work full force to get to that. But the reality is, is that things don't always turn out how we plan them. And when life happens, sometimes we have to make shifts, and we have to learn how to make the best of what we've got. So that was my story, basically, when I I mean, really, to give you kind of a full understanding, let me go back even to when I was a teenager, because I think it kind of starts at this point. When I was 16 years old, my parents went through a divorce, and it was, I mean, at that point in my life, but, you know, I'm a teenager, it's already hard to handle life, to manage life, but my world crumbled. Everything that I knew was a solid foundation for me, relationships that were closest to me, everything just crumbled beneath me, and at that point, I remember very vividly having two pathways of like I can decide to rebel and let this be my excuse for going down one path, or I can make a decision to not let this destroy me and to continue to follow my dreams. And I remember very vividly making that decision, but what I did when I made that decision is that I started to bury the pain and the hurt and basically try to survive like humans do, and just move forward, but I really buried everything in business, the busyness, in trying to accomplish my dream of becoming a pharmacist. Lesley Logan 6:23 Yeah, I'm sure no one listening knows what that is. All of our people are perfect. They don't over-achieve at all.Whitney Prude 6:31 They don't over-achieve and they don't bury their pain. They address everything as they come, they process everything. So, yeah, I'm human, right? And it actually took me a long time to accept that I was human and that I actually wasn't okay as I was burying all of those things. I did it for several years, and then I pushed myself through pharmacy school. And pharmacy school is literally the hardest thing that I've ever pushed myself through, because it just pushes you beyond, like, what, what survivable human, human limitations should be because it's just so demanding, and it really pushed me past my limits of what I could cover up. I couldn't cover up the pain anymore, and I just started having like these emotional meltdowns, like on a very, very regular basis. And essentially, I pushed myself to a point where I just, I crumbled. I came home from school one day I was completely exhausted. I felt like a zombie, nearly. I had so much studying I still had to do, and there was just this day where I crumbled to the floor and I just sobbed and I sobbed and I sobbed and I sobbed. I just I laid there, and it was just like I was completely broken. And that was really the, the turning point in my life where I was like, okay, I'm not okay. I can't cover it up anymore. I'm not okay. And so I started going to therapy. I started reading every self-help book possible that you know, that I could find. I was like, okay, I gotta do something, right? But the reality is I did get through pharmacy school, I got through residency, and I got this job at the Mayo Clinic. You know, it's like, oh, dream come true it's like, everything's fine, but the problem was, is that I had pushed myself too far, and I had pushed myself too hard, and I ended up developing an autoimmune disease about nine months into my job. Lesley Logan 8:20 Oh my gosh. Whitney Prude 8:21 So I had, yeah, nine months in, I had $200,000 of debt, student debt, hanging over my head and I couldn't use the computer. I was (inaudible) my whole job. I couldn't use the computer. I had a lot of limitations, a lot of restrictions. It's like, oh, you know, everything. I just need to let it heal my wrists and stuff will be fine. And that wasn't the case. I never came off of those restrictions. My limitations never changed. I couldn't do my job in the way that I ever you know, that I had imagined it being I was on disability, and at that point, I was like, what do I do now? How do you ever pay this loan off if I can't keep working as a pharmacist? And so that's where I started, you know, I was like exploring well, what would I do if I wasn't a pharmacist and I wanted to be a public speaker, and kind of, with that came coaching, and so that's when I started to explore some other things. But ultimately, what I decided I wanted to do, there's this, and I think that this maybe will be beneficial for some listeners, but I tried to find other people that could be inspiring to me, people that I knew had chronic illnesses, but I hadn't really looked into it very much. And one of the celebrities you can kind of hear more about their lives and stuff and so I came across Lady Gaga. I had never really been a fan of her before, but.Lesley Logan 9:35 Huge fan, huge fan, huge fan. (inaudible) I was at her first World Tour. Front row. Okay, anyways.Whitney Prude 9:46 And so, well, so I started listening to a lot of her interviews and stuff as she was talking about her chronic illness and she said something that was very, very powerful to me. And she said, "My pain really does me no good unless I can transform it into something that is." And so I took that to heart, and I said you know what, I am spending hours and hours and hours in bed every single day for months on end. And what I decided to do was to take that pain and all of this that I was dealing with. And I said, well, what I'm going to do is I'm going to turn it into a program to help people to avoid the pitfalls of what I have just gone through. I've lost so much of my life, so I'm going to now make it my life goal to help other people to avoid the pitfalls that I'm dealing with and have to deal with the rest of my life.Lesley Logan 10:34 Yeah. Oh, thank you for sharing that story and I love the idea of looking for people who inspire you who have similar issues, I think that is where people tend to also even go wrong in their inspiration. They pick someone out who has a different life than them, and they're like, I should be like them. That is a path. And it's like, I certainly don't want you to be inspired by other people outside, but also it's important for us to feel seen and heard and understood. And there have been people that I've compared myself to, and they inspire me as a female CEO. And it's like, yeah, they also had investors up the wazoo. We do not have the same life, we do not have the same abilities. I can have them as a North Star, but also like, can I be inspired by them, or should I find someone who's also gone through similar journeys, similar instances, similar growing up, so that I can feel a little bit more seen and also be inspired, because in spite of all of that, they have done other things. So that's really, really cool. So yeah, I mean, it's interesting. Like, autoimmunes are really–I was listening to Mindy Pelz and she was saying that the world we live in is killing women and more and more women have more autoimmune diseases than ever before, because of our society. And so it is true, because we push ourselves, because the way education systems are done is not anywhere in a way that is conducive to a cycle that a woman is going through and they're pushing this. And so you're inevitably going to have some sort of issue, whether it is a gut issue or an autoimmune issue. What are some of those things that you were telling people to like maybe be on the mind, watching out for that could be signs that could be affecting them or pushing them too far. And what are some of the things that you are doing to help people watch for those signs, or how we learn from your story so we don't end up in the same situation?Whitney Prude 12:18 Yeah, when I bring women into my program, I think some of the most common reoccurring things that I see, especially with women, is people-pleasing or we define ourselves as caretakers. And I think that also falls into being a mom. It's like when you're a mom, all of a sudden you have humans that are dependent on you to stay alive. And so a lot of times, we very much put ourselves on the back burner. So people-pleasing is a huge one. If you're taking care of everybody else, and if you're a yes woman, and you're saying yes to everybody else, but you don't have time to eat healthy, and you don't have time to exercise, and you don't have time to get enough sleep at night, those are key indicators that you're doing too much, that you're not taking care of yourself, that you've got to start switching your priorities and putting yourself at the top of your priority list, or you're not going to be able to keep showing up for those people. Lesley Logan 13:11 Yeah, so not at all what I expect you to say, and I'm loving it. I'm so grateful that you talk about people-pleasing and being too busy for self -care. There must be something in the moons, like I was talking to my girlfriend, and I don't want you to lose your train of thought. But I was talking to a girlfriend and she was like, I just don't have it in me to have that hustle. And I was like, you should see the morning routine I have so that I can do the job that I've created for myself that I love so much. And I was starting to feel like it sounded like luxurious and ridiculous. And then I was like, wait a minute, actually, no, this is what I need to be the best version of myself. There's nothing wrong with that. And I already tell people self-care isn't selfish care. So why is it, why am I thinking that I sound like it is selfish or luxurious. It's required. I need it. So I definitely, let's definitely get back to self-care in a moment. But thank you for bringing up people-pleasing because it is an epidemic. There's too many people who are people-pleasers, and it is costing us our lives. Whitney Prude 14:05 Well, and essentially, if you're a people-pleaser, you're very likely also an overachiever, like you're saying yes to way too many things, whether that's in the community or people you know, it's like at your kid's school, and they're asking you to do stuff, and then at church, they're asking you to do stuff, and then at work, they're asking you to do stuff, and if you're a yes woman, you're essentially overachieving. You're taking on everything, and you think that you're this rock star–in the long run, it's damaging, and it's going to show up. It's going to manifest when we push ourselves too hard internally, it is going to manifest, and usually it manifests in our physical health. So whether that's an autoimmune disease or it manifests in weight gain and bad diabetes, there's hundreds of ways that it can manifest, but the reality is, is that it will manifest. You cannot continue living like that the rest of your life and not have it lead to health issues. Lesley Logan 14:56 Yeah, yeah, everyone, rewind and re-listen to that again, because it is 100% my own experience. I also had student loans, but not, not nearly, not nearly what you had, but I also didn't walk out of it with a doctor degree and even a career. Liberal arts degree over here, everyone. I had a private school because that was smart. So that just means more expensive, everyone. So I was really trying to get out of this low-salary job and do what I loved, and I love doing it. So I told myself, it's fine that I'm working seven days a week because I love what I'm doing. And that was the overachiever in me. And what was happening is like my gut system was shutting down and I got dangerously underweight, and not because I wasn't eating, but because I wasn't digesting, absorbing nutrition. So my body was just not doing well and Facebook is showing me videos and pictures that I posted 10, 15, years ago, and I was like, that girl is, I can see how unhealthy she is. I could see it. I didn't see it then, because I'm just going and going and going and, like, living L.A. life where I have a 45-minute commute, and you just do that because that's the range you can afford. You just keep pushing and at some point you can't push anymore. And the problem is, is that now you're in a worse position, because it's actually harder to get out of that health situation than if you had made change, if I had made changes at the first signs of things. But no one told me–I think what the issue is and I think this is where listeners might also–I did seek help for some of the signs, and no one said, Hey, tell me about your workload. Tell me about, let's talk about a day in the life of you. Do you feel like you have time like, tell me about, what are you doing for? How's your sleep? No doctor was like asking me those things. And I do think that if someone had just actually put a mirror into my face, like you are actually not doing enough sleep, you're not, enough self-care, that I may have been able to shift it sooner. So I'm just wondering, like that's your experience as well.Whitney Prude 16:54 Oh yeah, 100% it's like when you do start noticing things like, where do we go? What do we do? We go to the doctor. And there's nothing wrong with going to the doctor, but the reality is that in the medical field, right? You're going to come in and they're looking at symptoms, and they're going to try to find a way to treat it, but we're not looking at what has driven us here. Why are we here? How do we make changes to actually change our lifestyle? A lot of it, you could reverse some of it, you can't, which is unfortunate, and you may require treatment, but we're not looking at the underlying root causes. And one of the things that I'm very, very passionate about is that usually, so if you look at people like, okay, we're people-pleasers, we're overachievers, we're perfectionists, whatever those things are, right? Whatever it is that we're pushing ourselves backwards and we're trying to please in the world. We're trying to, we're trying to feel worthy. We're trying to feel like we're enough. We're trying to feel loved. Well, where does this usually come from? The majority of it comes from our past. We go through our past and we're treated in a certain way, and there is no parent that is going to 100% meet your needs. Yeah, it's just not possible. They're human too, right? And so there's always going to be things where we don't feel good enough, or where we weren't recognized, or maybe only when we would really high achieve that's only the time that we were recognized. So now we're like, well, if I do everything perfect, then I can be loved and I can be good enough. And so we develop, over our lives, we develop these beliefs about ourselves, we develop these coping mechanisms, and they're all subconscious. Our brain does it on its own of like, how do we get this satisfaction out of the world that we need, essentially, and so we start doing all of these things in our lives to try to feel good enough and nobody ever teaches us how to show up for ourselves so that we can meet our own emotional needs and feel good enough inside of ourselves, so that we don't need any of that stuff. And none of that is ever going to be addressed when you go to the doctor. Never, never, never, never. It's the underlying cause for the majority of why people start getting sick.Lesley Logan 19:10 Oh my gosh. And for everyone we're not advocating, don't go the doctor, obviously, like, but we even have a female telemedicine that's a sponsor, so I love them. But also, just getting your symptoms treated is not the same as going, how did I get here in the first place? And so do you have tips for us, for the people who are listening, like, how do I meet my own needs? Or is this something that it obviously can't just be like three things and like, we've all nailed it. Obviously it takes coaching with you. But what are some areas we can see we're not meeting our own needs? Maybe that's a better way of looking at it. Whitney Prude 19:40 I mean, the first thing that I would say, and I like to challenge people to do this, just in general, if you sit down and write down your top five priorities, one through five. Okay, everybody sit down, write down your top priorities. Now the majority of people, when I have them, write down their top five priorities. At the end I ask, "And where are you on that list?" Nobody, almost no one puts themselves on that priority list. And where should you be and your health be on that priority list? It should be number one. Now everybody feels like that is selfish and it's 100% not selfish. It is essential. So you need to be at number one if you want to show up for your kids, if you want to show up for your husband, if you want to be here in 20 years when you have grandkids and you want to see their kids and whatever. You want all of that stuff to happen, then you've got to start putting yourself at number one. So you move yourself up to priority number one. You shift your kids down, you shift your husband down, you shift your work down, you shift everything down. And even, you know, some people are like, oh, no, well, God is most important. I have to do all this stuff for God, even that you cannot show up in this world and fulfill your true purpose for God if you are not prioritizing yourself and your health? So it doesn't matter. All of this stuff, you have to shift it down on the priority list, and you have to put yourself as number one. And when you start putting that into your focus every single day, it's like, well, have I met my own needs today? And people are bombarding you and asking you for all this stuff. If you haven't met your own needs, then the answer is no. You've got to start saying no. Lesley Logan 21:24 Oh my gosh, thank you for saying that. I've heard only one other person ever say, and this is not to knock men, but he was a male saying kids are number three. And I was like, I just feel like he gets away with that. He can say that, and every mom is not listening to that. They're, you know what I mean? They're not. They're putting the kids up first. And the relationship may be a second, but probably not. And honestly, he's like, you have to take care of you. And then if you have a partner, your partner's taking care of them, that's great. Then together, there's some way of making income, and the income is what fuels the payments for all the things. And then there's other people in your life, your children, family, other stuff. And he's like, it's gonna sound awful, but you can't provide for them if you don't take care of you, and you can't be there for them if you haven't made a way of providing. So it's like very difficult for people to understand. And I'm gonna get so many people saying kids should be number two. Obviously, if you have an infant, take care of the infant. But it'll be easier to take care of the infant if you've taken care of you before having the infant. And it's easier for your kids to be in a household where they have needs met, if the person who's meeting their needs has taken care of their own. It's just I don't like I used to teach so many moms that come in the school's asking to show up for things. They've got to do this thing for the household. The neighbor needs this. So all these different things, and they're talking about this in their session that's for them. And I was like, so this is like, for you. So like, maybe we, like, just, can we just, like, close the world off for a moment, this is actually for you. And when I kept telling them, like, we're doing this for you, so you could do all those things. I had those women coming three and four days a week, because it was the thing that they could tangibly feel was for them, it was like, why they were coming in, and it gave them the energy to do all this other stuff. And it's really cool. And we do have to remind people, we say this all the time on the podcast, which is why I'm, like, obsessed with you already, is like self-care is not selfish care. It is essential for you to be around. And the other unfortunate thing is, all the stuff that we do for self-care can feel very luxurious, like that's a word I mentioned, because you won't ever know what it prevented you from getting. You're not going to make it to the end and go, whoop, didn't get that autoimmune disease. Like you won't know because you did the things to prevent the burnout or the diseases or the illnesses, we don't get that information, so we tend to forget the self-care stuff when life gets hard. Whitney Prude 23:49 Yep, I think another important point to make as well is like, we talk about self-care, and I'll ask people like, do you genuinely love yourself? And they're like, oh yeah, well, I spend money, I buy myself clothes, I go get my nails done, I take care of myself, and I'm like, yes, but do you genuinely love yourself? Like self-love and self-care are two different things, right? So we have this element of are you showing up for yourself physically? Are you doing the things, you know it's like you're eating healthy? Are you exercising? Are you showing up for yourself physically? But on the flip side, and this is another thing that a lot of people miss, are you showing up for yourself emotionally? And do you know how?Lesley Logan 24:32 I think everyone just stopped and didn't know how to answer that. How did you learn that? Because I can't I mean, obviously that's something you had to learn, because you know, I'm not going to say you don't burn out if you love yourself, because I'm sure there's always room for an option, but I definitely think you would know it sooner than later. How did you learn that? How did you learn to self-love? How do you help people do that? Whitney Prude 24:56 Well, so my experience through this journey and my own self-love journey is kind of interesting. And you know, some people, anyone that's raised in like a pretty religious environment, could potentially relate. But within religion, there's a lot of expectations, and you're either doing the good things and meeting the expectations, (inaudible) or they're not, and you're not a good person, and you're a disappointment sort of a thing. It doesn't matter what religion it's like, these things exist, right? There are things that you're supposed to do and there are bad things. So for me, I had gotten, and it's not to say that the religion was bad in any sense of the word, but for me and my personality, I latched on to this of like, I can check the boxes and everyone thinks that I'm awesome, right, and it's praising me and I learned at one point in my life where my belief kind of started to, like, falter a little bit. I was like, wait a second, if I don't believe this and people aren't praising me, then, like, do I even freaking matter? Does anybody love me? Can I be loved, right? Like, if I'm not doing all of these things. Am I still lovable, or am I just this horrible, awful disappointment? And so I had to prove to myself, and I almost intentionally started doing the wrong things, because I had to prove to myself that it doesn't matter what I do or don't do, my worth doesn't change. And getting to the base of like, what's the value of a human being? Is value based on actions of how much you can accomplish? Or are you valuable because you are a living, breathing human being. It doesn't matter what you do or don't do. You're a unique individual that has value no matter what. And so my journey was associated with religion of like, where I felt this disappointment, because all of a sudden I was questioning like this, you know, this core belief that had brought me all of my self-worth, my whole life. And so then I had to start working to find myself like, well, can I be good enough? Can I be loved regardless? And I had to be the one that loved myself. I had to stop searching for all of these other people to fill that void. I had to start doing it for myself. Lesley Logan 27:06 Yeah, oh my gosh we could talk forever on I was raised in religion, and so we could talk forever about how that creates overachievers and this urge to always be doing and I think inherently, like, religion isn't bad. I think it's the way it's interpreted in people's bodies and emotions (inaudible) on them and so, yep, it's true, and it's interesting, because I don't know how much, even though I could quote some verses, which I'm not going to do that right now. But like, even though we are told that we are loved by the person we believe in, we are not taught to love ourselves the way that they love us, you know? And so going back to what you said at the beginning of this episode, it's like, how we are raised. Are we raising kids to love themselves? Are we teaching them that–I have a girlfriend who has her little girl, and she has like, little mirror things, and she's like, I'm beautiful and I'm loving, and she's doing this thing. She's like, I don't know if I (inaudible) in the mirror. And I'm like, I think it's really cool that she says, I'm beautiful and I'm loving, like she's having a whole little self-love moment every single day. Who cares what's in the mirror? You know? Like, I think that I didn't grow up like that. So we obviously know more today than we do. Every generation gets to have a little bit more insight. We get to learn from other people's journeys. But I think that is a really cool thing that we can all take away. Now that you are obviously now full time working for yourself and very aware of, like, why you're doing this and what you're doing. Who are you most excited to work with? And like, what brings you joy in doing this work? What are you hoping to help them achieve? And I hate the way I said achieved, like, helping them get or enjoy?Whitney Prude 28:39 Honestly, my favorite people to work with are women who don't know who they are, who are lost in their life. Because when they come into our program and they start digging, and it's hard to dig, you got to be brave, you know, and you got to say, okay, we're going to look inside, we're going to start paying attention to what my feelings are, and showing up and validating and recognizing that those feelings matter and that I deserve space in my own life. And so those women that come in and say, I'm not comfortable in my own skin, I don't really know who I am. Like I've lost myself. I don't know where I'm going, I don't know what to do, I don't know how to get out. Those are my absolute favorite people to work with, because when those women come into the program and we start digging and we start diving in, I mean, there's a lot of emotion, and there's a process that we take women through. They come because they want to lose weight, and they leave not even caring about the weight that they lost because they found themselves and they knew they know who they are and they're in control. They're able to now live a fulfilling life because they know how to show up for the woman that's staring back at them in the mirror. Those are one. 100% my absolute favorite clients to work with, because you just see this complete transformation. And it is absolutely incredible.Lesley Logan 30:10 I love that. Thank you for being so specific, because I do think there's a lot more people who are more aware that, like they're whelmed, like they're not, like they might not be overwhelmed, they're in the middle and they're kind of like, if you were to ask them, like, who are you really? Do you love yourself really? Those are some big questions that we don't have to face on a daily basis. Most people just ask us how we are, and they expect to say, I'm good, and then they get to know, I'm good too. Have a great day. Like, that's what most people expect. So most people are not asking themselves those big questions. And this is the Be It Till You See It podcast, and it's really hard to be it till you see it if you don't know who you are in the first place, it's a little bit difficult, you know? And so we've all been in places where, like, who am I really and where am I going? And like, do I matter? And am I lovable? And those are big questions that don't get answered overnight, but you do the work like your clients, or that you're saying your clients do, and then you get on the other side, and not only have the benefits of shedding weight in your instance, but also your client's sense, but also knowing exactly who you are and why you matter and what matters to you. So easy for us to focus on the outside. I need to fix this about me on the outside, and it's always, there's always an internal thing that is the root of it.Whitney Prude 31:23 If you think about, and this is, and I just say weight loss, just because, yeah, that's what, what brings a lot of people in, into my program. But if you think about someone so they want to reach a goal, right? They're like, okay, I want to lose 20 pounds. We don't like how we look. We want to get the scale down. Like, the motivation is very external, okay, but if you can take that motivation and you transition it from external to internal, and you get yourself to a point where you genuinely love yourself and you honor yourself, and you respect yourself, and you make yourself a priority, okay, so now it's coming from inside of yourself, then why do you eat healthy, and why do you exercise, and why do you get enough sleep? You do all of those things not because you want to change the scale. You do them because you genuinely care about yourself, you care about your body, you care about who you are, you care about how you feel like it all comes from inside of you, and it doesn't matter if the scale changes three pounds. Who cares now, right? You're gonna keep doing these things no matter what because you care about you. ,Lesley Logan 32:26 Yeah yeah. I think that's like, that's so good. I've been asking people what they do for self-care. I'm like, here's what I do for self-care. Like, what do you do for self-care? And I was on another person's podcast this week, and she's like, I got my nails done for self-care. Like, what do you do? And I'm like, prioritize my sleep. I try to drink enough water every day, you know, I make sure I'm feeding myself before I'm angry. I move my body intentionally for how my body is feeling that day, because I know I will be thankful tomorrow. I said, then, yes, I have a cold punch and I have a red light and I've got all these extra things, but like, the other thing that is listed are mostly free, if not things you are already buying at the grocery store as it is. So like, how you're choosing to see them. And I think people don't realize that they have control over self-care without changing that much in their schedule. It can be more intentional about when they go to bed and what they do before bed, and what they're feeding themselves with. And it's so easy to say that because I know how badly I felt when I wasn't making those intentional decisions, because I wasn't loving myself and I wasn't caring for myself. I said I'll do that tomorrow. Oh, when I have more time or I have my money, then I'm more deserving when I've done this, and I'm more deserving of x and y things, and it's actually like your future person is deserving of it now, but that it comes with self-love, like you said. Oh, cool stuff. Whitney. Okay, we're gonna take a brief break and we're gonna come back and find out where people find you, follow you, work with you and your Be It Action Items. Lesley Logan 33:54 All right, Whitney, where can people connect with you more if they want to dive in deeper with you? What do you got for us? Whitney Prude 33:58 Yeah, the best place to connect with me, first of all is on Instagram. You can always message me on Instagram. My Instagram is @mywholeandhappylife. Just send us a message. We're always in Instagram responding to messages. Happy to answer any questions. Lesley Logan 34:14 Amazing. Okay, you have given us a lot to ponder already. So I'm just gonna say, like, the transcripts of this are gonna have some great questions for you to ask yourself. But we always love the for the overachiever, perfectionist, the action step that people can take to be uit till they see it. What bold, executable, intrinsic or target steps can we take? What do you have for us?Whitney Prude 34:34 So I think what kind of goes along with the conversation that we've had today in talking about helping women to really dive in and find themselves. The step that I would encourage people to take is to lean into the discomfort. Now, the reason that I say that is because if you want to change, change is uncomfortable. So. So your body will be telling you what you need to change, because it will feel uncomfortable. Maybe you don't express yourself, you don't share your feelings, and you feel uncomfortable. Your stomach drops. You're like, like, you know it's like our bodies often will tell us the things that we need to be working on, that we need to do, but we have to lean into that discomfort. We have to recognize it, and then we have to start forcing ourselves to actually do the thing that's uncomfortable. So then you have to start actually speaking up, whether it's like looking inside of ourselves, or if it's prioritizing ourselves, even when we feel selfish, that's uncomfortable. I have clients where it's like you have to schedule 10 minutes of nothing in your schedule. That is just time where you sit like you are just spending time with yourself. Put it in your schedule, on your calendar, non-negotiable. And it's almost overwhelming. They're like, I can't even comprehend spending that 10 minutes with myself, right? You have to start pushing yourself into that discomfort. So in talking about self-love, in talking about self-care, my action step would be to really plan that time for yourself, put it on your calendar, non-negotiable. Same time every day. This is your time, and you have to just sit in it, no matter how uncomfortable it is, start sitting in the discomfort and it will get more comfortable. But you have to get into the discomfort before you're ever going to make progress towards change. Lesley Logan 36:33 Yeah. I was just talking to some of the girls in my mentorship program, they're Pilates teachers, and they're like, yeah, my client complains it's uncomfortable. And I was like, so it's not painful, just like, No. And I'm like, well, then, yeah, it's uncomfortable. We're doing something different in her body. Like, no, we need to it's okay to say. It's okay. It's okay to be uncomfortable. Not everything is comfortable in life, changing our strength, changing our alignment, changing our posture, is going to be uncomfortable because it is different than what we are used to. Pain is a different story, and so it's just really funny, because we all want the thing or the goal or the achievement or whatever it is, but to get there, because we don't have it now, it's going to take some discomfort and changing who we are to be there. So I love that. It's great. It's great. Whitney, you're awesome. This has been a wonderful conversation. I'm fired up. I'm excited. I am definitely checking myself on my self-love after this, what a great thing to just do a check in on everyone. How are you gonna use these tips in your life? Please let us know. Make sure you tag Whitney and her team and let them know how this episode affected you. And if you are needing more of this. Reach out to Whitney, because obviously, like, wow, definitely struck some good chords in here. And until next time, Be It Till You See It. Lesley Logan 37:49 That's all I got for this episode of the Be It Till You See It Podcast. One thing that would help both myself and future listeners is for you to rate the show and leave a review and follow or subscribe for free wherever you listen to your podcast. Also, make sure to introduce yourself over at the Be It Pod on Instagram. I would love to know more about you. Share this episode with whoever you think needs to hear it. Help us and others Be It Till You See It. Have an awesome day. Be It Till You See It is a production of The Bloom Podcast Network. If you want to leave us a message or a question that we might read on another episode, you can text us at +1-310-905-5534 or send a DM on Instagram @BeItPod. Brad Crowell 38:32 It's written, filmed, and recorded by your host, Lesley Logan, and me, Brad Crowell. Lesley Logan 38:37 It is transcribed, produced and edited by the epic team at Disenyo.co. Brad Crowell 38:41 Our theme music is by Ali at Apex Production Music and our branding by designer and artist, Gianfranco Cioffi. Lesley Logan 38:48 Special thanks to Melissa Solomon for creating our visuals. Brad Crowell 38:51 Also to Angelina Herico for adding all of our content to our website. And finally to Meridith Root for keeping us all on point and on time. Support this podcast at — https://redcircle.com/be-it-till-you-see-it/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
Host: Denise M. Dupras, M.D., Ph.D. Guest: Isa J. Houwink, M.D., Ph.D. Pharmacogenomics (PGx) is transforming everyday primary care practice. By using patients' genetic profiles, providers are guiding more precise, personalized treatments. In this episode of Genes & Your Health podcast, primary care physicians Dr. Denise Dupra and Dr. Isa J. Houwink discuss their practical applications and integration of PGx. The tips, tools and case studies shared, including how to optimize medication outcomes, reduce adverse drug reactions and deliver better patient care, is beneficial for all primary care providers. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
Pharmacogenomics plays a critical role in personalised medicine, as some adverse drug reactions are genetically determined. Adverse drugs reactions (ADRs) account for 6.5% of hospital admissions in the UK, and the application of pharmacogenomics to look at an individuals response to drugs can significantly enhance patient outcomes and safety. In this episode, our guests discuss how genomic testing can identify patients who will respond to medications and those who may have adverse reactions. We hear more about Genomics England's collaboration with the Medicines and Healthcare products Regulatory Agency in the Yellow Card Biobank and our guests discuss the challenges of implementing pharmacogenomics into the healthcare system. Our host Vivienne Parry, Head of Public Engagement at Genomics England, is joined by Anita Hanson, Research Matron and the Lead Research Nurse for clinical pharmacology at Liverpool University Hospitals NHS Foundation Trust, and Professor Bill Newman, Professor of translational genomic medicine at the Manchester Center for Genomic Medicine, and Professor Matt Brown, Chief Scientific Officer at Genomics England. "I think we're moving to a place where, rather than just doing that one test that might be relevant to one drug, we'd be able to do a test which at the same price would generate information that could be relevant at further points in your life if you were requiring different types of medicine. So, that information would then be available in your hospital record, in your GP record, that you could have access to it yourself. And then I think ultimately what we would really love to get to a point is where everybody across the whole population just has that information to hand when it's required, so that they're not waiting for the results of a genetic test, it's immediately within their healthcare record." To learn more about Jane's lived experience with Stevens-Johnson syndrome, visit The Academy of Medical Sciences' (AMS) YouTube channel. The story, co-produced by Areeba Hanif from AMS, provides an in-depth look at Jane's journey. You can watch the video via this link: https://www.youtube.com/watch?v=v4KJtDZJyaA Want to learn more about personalised medicine? Listen to our Genomics 101 episode where Professor Matt Brown explains what it is in less than 5 minutes: https://www.genomicsengland.co.uk/podcasts/genomics-101-what-is-personalised-medicine You can read the transcript below or download it here: https://www.genomicsengland.co.uk/assets/documents/Podcast-transcripts/Can-genomic-testing-prevent-adverse-drug-reactions.docx Vivienne: Hello and welcome to Behind the Genes. Bill: What we've seen is that the limited adoption so far in the UK and other countries has focused particularly on severe adverse drug reactions. They've been easier to identify and there's a clear relationship between some drugs and some genetic changes where that information is useful. So, a good example has been the recent adoption of pharmacogenetic testing for a gene called DPYD for patients undergoing cancer treatment, particularly breast and bowel cancer. And if you have an absence of the enzyme that that gene makes, if you're given that treatment, then you can end up on intensive care and die, so it's a really significant side effect. But as you say, the most common side effects aren't necessarily fatal, but they can have a huge impact upon people and on their wellbeing. Vivienne: My name's Vivienne Parry and I'm head of public engagement at Genomics England, and today we'll be discussing the critical role of pharmacogenomics in personalised medicine, highlighting its impact on how well medicines work, their safety, and on patient care. I'm joined today by Professor Bill Newman, professor of translational genomic medicine at the Manchester Centre for Genomic Medicine, Anita Hanson, research matron, a fabulous title, and lead research nurse for clinical pharmacology at the Liverpool University Hospital's NHS Foundation Trust, and Professor Matt Brown, chief scientific officer for Genomics England. And just remember, if you enjoy today's episode, we'd love your support, so please like, share and rate us on wherever you listen to your podcasts. So, first question to you, Bill, what is pharmacogenomics? Bill: Thanks Viv. I think there are lots of different definitions, but how I think of pharmacogenetics is by using genetic information to inform how we prescribe drugs, so that they can be safer and more effective. And we're talking about genetic changes that are passed down through families, so these are changes that are found in lots of individuals. We all carry changes in our genes that are important in how we transform and metabolise medicines, and how our bodies respond to them. Vivienne: Now, you said pharmacogenetics. Is it one of those medicine things like tomato, tomato, or is there a real difference between pharmacogenetics and pharmacogenomics? Bill: So, people, as you can imagine, do get quite irate about this sort of thing, and there are lots of people that would contest that there is a really big important difference. I suppose that pharmacogenetics is more when you're looking at single changes in a relatively small number of genes, whereas pharmacogenomics is a broader definition, which can involve looking at the whole genome, lots of genes, and also whether those genes are switched on or switched off, so the expression levels of those genes as well would encompass pharmacogenomics. But ultimately it's using genetic information to make drug prescription safer and more effective. Vivienne: So, we're going to call it pharmacogenomics and we're talking about everything, that's it, we'll go for it. So Matt, just explain if you would the link between pharmacogenomics and personalised medicine. And I know that you've done a big Genomics 101 episode about personalised medicine, but just very briefly, what's the link between the two? Matt: So, personalised medicine's about using the right dose of the right drug for the right individual. And so pharmacogenomics helps you with not only ensuring that you give a medication which doesn't cause problems for the person who receives it, so an adverse drug reaction, but also that they're actually getting the right dose. Of course, people's ability to metabolise, activate and respond to drugs genetically is often genetically determined, and so sometimes you need to adjust the dose up or down according to a person's genetic background. Vivienne: Now, one of the things that we've become very aware of is adverse drug reactions, and I think they account for something like six and a half percent of all hospital admissions in the UK, so it's absolutely huge. Is that genetically determined adverse drug reactions? Matt: So, the answer to that is we believe so. There's quite a bit of data to show that you can reduce the risk of people needing a hospital admission by screening genetic markers, and a lot of the very severe reactions that lead to people being admitted to hospital are very strongly genetically determined. So for example, there are HLA types that affect the risk of adverse drug reactions to commonly used medications for gout, for epilepsy, some HIV medications and so on, where in many health services around the world, including in England, there are already tests available to help prevent those leading to severe reactions. It's likely though that actually the tests we have available only represent a small fraction of the total preventable adverse drug reactions were we to have a formal pre-emptive pharmacogenomics screening programme. Vivienne: Now, I should say that not all adverse drug reactions are genetic in origin. I mean, I remember a rather nasty incident on the night when I got my exam results for my finals, and I'd actually had a big bee sting and I'd been prescribed antihistamines, and I went out and I drank rather a lot to celebrate, and oh my goodness me, I was rather ill [laughter]. So, you know, not all adverse drug reactions are genetic in origin. There are other things that interact as well, just to make that clear to people. Matt: Yes, I think that's more an interaction than an adverse drug reaction. In fact frankly, the most common adverse drug reaction in hospitals is probably through excess amounts of water, and that's not medically determined, that's the prescription. Vivienne: Let me now come to Anita. So, you talk to patients all the time about pharmacogenomics in your role. You've been very much involved in patient and public involvement groups at the Wolfson Centre for Personalised Medicine in Liverpool. What do patients think about pharmacogenomics? Is it something they welcome? Anita: I think they do welcome pharmacogenomics, especially so with some of the patients who've experienced some of the more serious, life threatening reactions. And so one of our patients has been doing some work with the Academy of Medical Sciences, and she presented to the Sir Colin Dollery lecture in 2022, and she shared her story of having an adverse drug reaction and the importance of pharmacogenomics, and the impact that pharmacogenomics can have on patient care. Vivienne: Now, I think that was Stevens-Johnson syndrome. We're going to hear in a moment from somebody who did experience Stevens-Johnson's, but just tell us briefly what that is. Anita: Stevens-Johnson syndrome is a potentially life threatening reaction that can be caused by a viral infection, but is more commonly caused by a medicine. There are certain groups of medicines that can cause this reaction, such as antibiotics or anticonvulsants, nonsteroidal anti-inflammatories, and also a drug called allopurinol, which is used to treat gout. Patients have really serious side effects to this condition, and they're often left with long-term health complications. The morbidity and mortality is considerable as well, and patients often spend a lot of time in hospital and take a long time to recover. Vivienne: And let's now hear from Jane Burns for someone with lived experience of that Stevens-Johnson syndrome. When Jane Burns was 19, the medicine she took for her epilepsy was changed. Jane: I remember waking up and feeling really hot, and I was hallucinating, so I was taken to the Royal Liverpool Hospital emergency department by my parents. When I reached A&E, I had a temperature of 40 degrees Celsius. I was given Piriton and paracetamol, and the dermatologist was contacted. My mum had taken my medication to hospital and explained the changeover process with my epilepsy medication. A decision was made to discontinue the Tegretol and I was kept in for observation. Quite rapidly, the rash was changing. Blisters were forming all over my body, my mouth was sore and my jaw ached. My temperature remained very high. It was at this point that Stevens-Johnson syndrome, or SJS, was diagnosed. Over the next few days, my condition deteriorated rapidly. The rash became deeper in colour. Some of the blisters had burst, but some got larger. I developed ulcers on my mouth and it was extremely painful. I started to lose my hair and my fingernails. As I had now lost 65 percent of my skin, a diagnosis of toxic epidermal necrolysis, or TEN, was made. Survivors of SJS TEN often suffer with long-term visible physical complications, but it is important to also be aware of the psychological effects, with some patients experiencing post-traumatic stress disorder. It's only as I get older that I realise how extremely lucky I am to have survived. Due to medical and nursing expertise, and the research being conducted at the time, my SJS was diagnosed quickly and the medication stopped. This undoubtedly saved my life. Vivienne: Now, you've been looking at the development of a passport in collaborating with the AMS and the MHRA. Tell me a bit more about that. Anita: Yes, we set up a patient group at the Wolfson Centre for Personalised Medicine approximately 12 years ago, and Professor Sir Munir Pirmohamed and I, we wanted to explore a little bit more about what was important to patients, really to complement all the scientific and clinical research activity within pharmacogenomics. And patients recognised that, alongside the pharmacogenomic testing, they recognised healthcare professionals didn't really have an awareness of such serious reactions like Stevens-Johnson syndrome, and so they said they would benefit from having a My SJS Passport, which is a booklet that can summarise all of the important information about their care post-discharge, and this can then be used to coordinate and manage their long-term healthcare problems post-discharge and beyond. And so this was designed by survivors for survivors, and it was then evaluated as part of my PhD, and the findings from the work suggest that the passport is like the patient's voice, and it really does kind of validate their diagnosis and raises awareness of SJS amongst healthcare professionals. So, really excellent findings from the research, and the patients think it's a wonderful benefit to them. Vivienne: So, it's a bit like a kind of paper version of the bracelet that you sometimes see people wearing that are on steroids, for instance. Anita: It is like that, and it's wonderful because it's a handheld source of valuable information that they can share with healthcare professionals. And this is particularly important if they're admitted in an emergency and they can't speak for themselves. And so the passport has all that valuable information, so that patients aren't prescribed that drug again, so it prevents them experiencing a serious adverse drug reaction again. Vivienne: So, Stevens-Johnson, Bill, is a really scary side effect, but what about the day to day benefits of pharmacogenomics for patients? Bill: So, what we've seen is that the limited adoption so far in the UK and other countries has focused particularly on severe adverse drug reactions. They've been easier to identify and there's a clear relationship between some drugs and some genetic changes where that information is useful. So a good example has been the recent adoption of pharmacogenetic testing for a gene called DPYD for patients undergoing cancer treatment, particularly breast and bowel cancer. And if you have an absence of the enzyme that that gene makes, if you're given that treatment, then you can end up on intensive care and die, so it's a really significant side effect. But as you say, the most common side effects aren't necessarily fatal, but they can have a huge impact upon people and on their wellbeing. And it's not just in terms of side effects. It's in terms of the effectiveness of the medicine. Because if a person is prescribed a medicine that doesn't or isn't going to work for them then it can take them longer to recover, to get onto the right medicine. That can have all sorts of detrimental effects. And so when we're thinking about introducing pharmacogenetics more broadly rather than just on a single drug or a single gene basis, we're thinking about that for common drugs like antidepressants, painkillers, statins, the drugs that GPs are often prescribing on a regular basis to a whole range of patients. Vivienne: So, to go back to you, Anita, we're really talking about dose here, aren't we, whether you need twice the dose or half the dose depending on how quickly your body metabolises that particular medicine. How do patients view that? Anita: Well, the patient in question who presented for the Academy of Medical Sciences, I mean, her take on this was, she thinks pharmacogenetics is wonderful because it will allow doctors and nurses to then prescribe the right drug, but also to adapt the dose accordingly to make sure that they get the best outcome, which provides the maximum benefit while also minimising any potential harm. And so from her perspective, that was one of the real benefits of pharmacogenomics. But she also highlighted about the benefits for future generations, the fear of her son taking the same medicine and experiencing the same reaction. And so I think her concerns were, if we have pharmacogenetic testing for a panel of medicines, as Bill mentioned then, then perhaps this would be fantastic for our children as they grow up, and we can identify and predict and prevent these type of reactions happening to future generations. Vivienne: And some of these drugs, Bill, are really very common indeed, something like codeine. Just tell us about codeine, ‘cos it's something – whenever I tell this to friends [laughter], they're always completely entranced by the idea that some people don't need nearly as much codeine as others. Bill: Yeah, so codeine is a drug that's very commonly used as a painkiller. To have its real effect, it needs to be converted in the body to a different drug called morphine, and that is done by an enzyme which is made by a gene called CYP2D6. And we all carry changes in CYP2D6, and the frequency of those variants, whether they make the gene work too much or whether they make it work too little, they vary enormously across the world, so that if you go to parts of Africa, about 30 percent of the population will make more of the CYP2D6, and so they will convert the codeine much more quickly, whereas if you go to the UK, maybe up to ten percent of the white population in the UK just won't be converting codeine to morphine at all, so they won't get any benefit from the drug. So at both ends, you have some people that don't respond and some people that respond a little bit too much so that they need either an alternative drug or they need a different dose. Vivienne: So, all those people who say, you know, “My headache hasn't been touched by this painkiller,” and we say, “What a wimp you're being,” actually, it's to do with genetics. Bill: Yeah, absolutely. There's a biological reason why people don't – not for everybody, but for a significant number of people, that's absolutely right, and we can be far more tailored in how we prescribe medication, and get people onto painkillers that work for them much more quickly. Vivienne: And that's so interesting that it varies by where you come from in the world, because that means we need to give particular attention – and I'm thinking, Anita, to working with patients from different community groups, to make sure that they understand the need for pharmacogenomics. Anita: I think that's really important, Vivienne, and I think we are now having discussions with the likes of Canada SJS awareness group, and also people have been in touch with me from South Africa because people have requested the passport now to be used in different countries, because they think it's a wonderful tool, and it's about raising awareness of pharmacogenomics and the potential benefits of that, and being able to share the tools that we've got to help patients once they've experienced a serious reaction. Vivienne: So, pharmacogenomics clearly is important in the prevention of adverse drug reactions, better and more accurate prescribing, reduced medicines wastage. Does this mean that it's also going to save money, Bill, for the NHS? Bill: Potentially. It should do if it's applied properly, but there's lots of work to make sure that not only are we using the right evidence and using the right types of tests in the laboratory, but we're getting the information to prescribers, so to GPs, to pharmacists, to hospital doctors, in a way that is understandable and meaningful, such that they can then act upon that information. So, the money will only be saved and then can be reused for healthcare if the whole process and the whole pathway works, and that information is used effectively. Vivienne: So, a lot of research to make sure that all of that is in place, and to demonstrate the potential cost savings. Bill: Yes. I mean, there are very nice studies that have been done already in parts of the world that have shown that the savings that could be accrued for applying pharmacogenetics across common conditions like depression, like in patients to prevent secondary types of strokes, are enormous. They run into hundreds of millions of pounds or dollars. But there is an initial investment that is required to make sure that we have the testing in place, that we have the digital pathways to move the information in place, and that there's the education and training, so that health professionals know how to use the information. But the potential is absolutely enormous. Vivienne: Matt, can I turn now to the yellow card. So, people will be very familiar with the yellow card system. So, if you have an adverse reaction, you can send a yellow card in – I mean, literally, it is a yellow card [laughter]. It does exactly what it says on the tin. You send a yellow card to the MHRA, and they note if there's been an adverse effect of a particular medicine. But Genomics England is teaming up with the MHRA to do something more with yellow cards, and we're also doing this with the Yellow Card Biobank. Tell us a bit more. Matt: So, yellow card's a great scheme that was set up decades ago, initially starting off, as you said, with literally yellow cards, but now actually most submissions actually come online. And it's important to note that submissions can come not just from healthcare providers, but majority of submissions actually come from patients themselves, and that people should feel free, if they feel they've had an adverse drug reaction, to report that themselves rather than necessarily depending on a medical practitioner or the healthcare provider to create that report. So, Genomics England is partnering with the MHRA in building what's called the Yellow Card Biobank, the goal of which is to identify genetic markers for adverse drug reactions earlier than has occurred in the past, so that we can then introduce genetic tests to prevent these adverse drug reactions much sooner than has occurred previously. So, what we're doing is basically at the moment we're doing a pilot, but the ultimate plan is that in future, patients who report a serious adverse drug reaction through the Yellow Card Biobank will be asked to provide a sample, a blood sample, that we then screen. We do a whole genome sequence on it, and then combine these with patients who've had like adverse drug reactions and identify genetic markers for that adverse drug reaction medication earlier, that can then be introduced into clinical practice earlier. And this should reduce by decades the amount of time between when adverse drug reactions first start occurring with medications and us then being able to translate that into a preventative mechanism. Vivienne: And will that scheme discover, do you think, new interactions that you didn't know about before? Or do you expect it to turn up what you already know about? Matt: No, I really think there's a lot of discovery that is yet to happen here. In particular, even for drugs that we know cause adverse drug reactions, mostly they've only been studied in people of European ancestry and often in East Asian ancestry, but in many other ancestries that are really important in the global population and in the UK population, like African ancestry and South Asian ancestries, we have very little data. And even within Africa, which is an area which is genetically diverse as the rest of the world put together, we really don't know what different ethnicities within Africa, actually what their genetic background is with regard to adverse drug reactions. The other thing I'd say is that there are a lot of new medications which have simply not been studied well enough. And lastly, that at the moment people are focused on adverse drug reactions being due to single genetic variants, when we know from the model of most human diseases that most human diseases are actually caused by combinations of genetic variants interacting with one another, so-called common disease type genetics, and that probably is similarly important with regard to pharmacogenomics as it is to overall human diseases. That is, it's far more common that these are actually due to common variants interacting with one another rather than the rare variants that we've been studying to date. Vivienne: So, it's a kind of cocktail effect, if you like. You know, you need lots of genes working together and that will produce a reaction that you may not have expected if you'd looked at a single gene alone. Matt: That's absolutely correct, and there's an increasing amount of evidence to show that that is the case with medications, but it's really very early days for research in that field. And the Yellow Card Biobank will be one of many approaches that will discover these genetic variants in years to come. Vivienne: Now, Matt's a research scientist. Bill, you're on the frontline in the NHS. How quickly can this sort of finding be translated into care for people in the NHS? Bill: So, really quickly is the simple answer to that, Viv. If we look at examples from a number of years ago, there's a drug called azathioprine that Matt has used lots in some of his patients. In rheumatology, it's used for patients with inflammatory bowel disease. And the first studies that showed that there was a gene that was relevant to having bad reactions to that drug came out in the 1980s, but it wasn't until well into this century, so probably 30-plus years later that we were routinely using that test in clinical medicine. So, there was an enormous lot of hesitancy about adopting that type of testing, and a bit of uncertainty. If you move forward to work that our colleague Munir Pirmohamed in Liverpool has done with colleagues in Australia like Simon Mallal around HIV medicine, there was this discovery that a drug called abacavir, that if you carried a particular genetic change, that you had a much higher risk of having a really severe reaction to that. The adoption from the initial discovery to routine, worldwide testing happened within four years. So, already we've seen a significant change in the appetite to move quickly to adopt this type of testing, and I see certainly within the NHS and within other health systems around the world, a real desire to adopt pharmacogenetics into routine clinical practice quickly and at scale, but also as part of a broader package of care, which doesn't just solely focus on genetics, but thinks about all the other parts that are important in how we respond to medication. So, making sure we're not on unusual combinations of drugs, or that we're taking our medicine at the right time and with food or not with food, and all of those other things that are really important. And if you link that to the pharmacogenetics, we're going to have a much safer, more effective medicines world. Vivienne: I think one of the joys of working at Genomics England is that you see some of this work really going into clinical practice very fast indeed. And I should say actually that the Wolfson Centre for Personalised Medicine, the PPI group that Anita looks after so well, they've been very important in recruiting people to Yellow Card Biobank. And if anyone's listening to this, Matt, and wants to be part of this, how do they get involved? Or is it simply through the yellow card? Matt: So at the moment, the Yellow Card Biobank is focusing on alopurinol. Vivienne: So, that's a medicine you take for gout. Matt: Which I use a lot in my rheumatology clinical practice. And direct acting oral anticoagulants, DOACs, which are used for vascular disease therapies and haemorrhage as a result of that. So, the contact details are available through the MHRA website, but I think more importantly, it's just that people be aware of the yellow card system itself, and that if they do experience adverse drug reactions, that they do actually complete a report form, ‘cos I think still actually a lot of adverse drug reactions go unreported. Vivienne: I'm forgetting of course that we see Matt all the time in the Genomics England office and we don't think that he has any other home [laughter] than Genomics England, but of course he still sees some patients in rheumatology clinic. So, I want to now look to the future. I mean, I'm, as you both know, a huge enthusiast for pharmacogenomics, ‘cos it's the thing that actually, when you talk to patients or just the general public, they just get it straight away. They can't think why, if you knew about pharmacogenomics, why you wouldn't want to do it. But it's not necessarily an easy thing to do. How can we move in the future, Bill, to a more proactive approach for pharmacogenomics testing? Where would we start? Bill: Yes, so I think we've built up really good confidence that pharmacogenetics is a good thing to be doing. Currently, we're doing that predominantly at the point when a patient needs a particular medicine. That's the time that you would think about doing a genetic test. And previously, that genetic test would only be relevant for that specific drug. I think we're moving to a place where, rather than just doing that one test that might be relevant to one drug, we'd be able to do a test which at the same price would generate information that could be relevant at further points in your life if you were requiring different types of medicine. So, that information would then be available in your hospital record, in your GP record, that you could have access to it yourself. And then I think ultimately what we would really love to get to a point is where everybody across the whole population just has that information to hand when it's required, so that they're not waiting for the results of a genetic test, it's immediately within their healthcare record. That's what we'd call pre-emptive pharmacogenetic testing, and I think that's the golden land that we want to reach. Vivienne: So for instance, I might have it on my NHS app, and when I go to a doctor and they prescribe something, I show my app to the GP, or something pops up on the GP's screen, or maybe it's something that pops up on the pharmacist's screen. Bill: I think that's right. I think that's what we're looking to get to that point. We know that colleagues in the Netherlands have made some great progress at developing pathways around that. There's a lot of public support for that. And pharmacists are very engaged in that. In the UK, the pharmacists, over the last few years, have really taken a very active role to really push forward this area of medicine, and this should be seen as something that is relevant to all people, and all health professionals should be engaged with it. Vivienne: And on a scale of one to ten, how difficult is it going to be to implement in the NHS? Bill: So, that's a difficult question. I think the first thing is identifying what the challenges are. So I have not given you a number, I've turned into a politician, not answered the question. So, I think what has happened over the last few years, and some of our work within the NHS Network of Excellence in pharmacogenetics and some of the other programmes of work that have been going on, is a really good, honest look at what it is we need to do to try to achieve pharmacogenetics implementation and routine use. I don't think the challenge is going to be predominantly in the laboratory. I think we've got phenomenal laboratories. I think we've got great people doing great genetic testing. I think the biggest challenges are going to be about how you present the data, and that data is accessible. And then ensuring that health professionals really feel that this is information that isn't getting in the way of their clinical practice, but really making a difference and enhancing it, and of benefit both to the healthcare system but more importantly to the patients. Vivienne: Now, when I hear you both talk, my mind turns to drug discovery and research, and Matt, I'm quite sure that that's right at the top of your mind. Tell us how pharmacogenomics can help in drug discovery and research. Matt: So, pharmacogenomics, I think actually just genetic profiling of diseases in itself just to start off with is actually a really good way of identifying new potential therapeutic targets, and also from derisking drug development programmes by highlighting likely adverse drug reactions of medications that are being considered for therapeutic trials, or targets that are being considered for therapeutic development. Pharmacogenomics beyond that is actually largely about – well, it enables drug development programmes by enabling you to target people who are more likely to respond, and avoid people who are more likely to have adverse drug reactions. And so that therapeutic index of the balance between likely efficacy versus likely toxicity, genetics can really play into that and enable medications to be used where otherwise they might have failed. This is most apparent I think in the cancer world. A classic example there, for example, is the development of a class of medications called EGFR inhibitors, which were developed for lung cancer, and in the initial cancer trials, actually were demonstrated to be ineffective, until people trialled them in East Asia and found that they were effective, and that that turns out to be because the type of cancers that respond to them are those that have mutations in the EGFR gene, and that that's common in East Asians. We now know that, wherever you are in the world, whether you're East Asian or European or whatever, if you have a lung adenocarcinoma with an EGFR mutation, you're very likely to respond to these medications. And so that pharmacogenomic discovery basically rescued a class of medication which is now probably the most widely used medication for lung adenocarcinomas, so a huge beneficial effect. And that example is repeated across multiple different cancer types, cancer medication types, and I'm sure in other fields we'll see that with expansive new medications coming in for molecularly targeted therapies in particular. Vivienne: So, smaller and more effective trials rather than larger trials that perhaps seem not to work but actually haven't been tailored enough to the patients that are most likely to benefit. Matt: Yeah, well, particularly now that drug development programmes tend to be very targeted at specific genetic targets, pharmacogenetics is much more likely to play a role in identifying patients who are going to respond to those medications. So, I think many people in the drug development world would like to see that, for any significant drug development programme, there's a proper associated pharmacogenomic programme to come up with molecular markers predicting a response. Vivienne: We're going to wrap up there. Thank you so much to our guests, Bill Newman, Anita Hanson, Matt Brown, and our patient Jane Burns. Thank you so much for joining us today to discuss pharmacogenomics in personalised medicine, and the benefits, the challenges and the future prospects for integrating pharmacogenomics into healthcare systems. And if you'd like to hear more podcasts like this, please subscribe to Behind the Genes. It's on your favourite podcast app. Thank you so much for listening. I've been your host, Vivienne Parry. This podcast was edited by Bill Griffin at Ventoux Digital and produced by the wonderful Naimah. Bye for now.
Welcome to episode 051 of Life Sciences 360.We welcome Howard McLeod, a distinguished expert in precision medicine and pharmacogenomics. Howard shares his profound journey into the world of personalized medicine, emphasizing the significant impact of individualized treatments on cancer patients. From groundbreaking gene discoveries to advising cutting-edge biotech companies, Howard's work underscores the value of targeted therapies and their potential to transform patient outcomes.Howard also discusses his current roles, including his position as the Center Director for Precision Medicine and Functional Genomics at Utah Tech and his advisory role in several companies. He shares insights into exciting projects aimed at improving drug response predictions and mental health treatments for university students through pharmacogenomics.Chapters 00:00 - Introduction and Guest Welcome01:00 - The Importance of Experimental Therapies02:00 - Career Inspiration and Key Moments04:00 - Mentors and Lessons Learned06:00 - Practical Applications of Research08:00 - Staying Grounded in Patient Care10:00 - Current Roles and Projects12:00 - Addressing Mental Health in Students14:00 - Integrating Technology in Medicine18:00 - Simplifying Complex Medical Information22:00 - Reflections on Technological Advancements26:00 - Embracing Change and New Challenges30:00 - Final Thoughts and Future Outlook36:00 - Closing Remarks and Contact InformationThis episode is a treasure trove of insights for anyone interested in precision medicine, pharmacogenomics, and the future of healthcare. Don't miss Howard McLeod's inspiring journey and the valuable lessons he shares!-----Links:*Dr. Howard McLeod LinkedIn ( https://www.linkedin.com/in/howard-mcleod-90866a12/)*Harsh Thakkar LinkedIn (https://www.linkedin.com/in/harshvthakkar/)*Listen to this episode on the go!
Careblazers, I'm thrilled to share an enlightening conversation with Dr. Adrijana Kekic, a top expert in pharmacogenomics. We dive into how our unique genetic makeup can significantly influence the way we respond to medications, challenging the common one-size-fits-all approach to prescribing. This discussion is packed with crucial insights on the power of pharmacogenomic testing to prevent misdiagnoses and enhance treatment effectiveness, especially for conditions often mistaken for dementia.
Pharmacogenomics (PGx) is a rapidly evolving field of precision medicine that studies how genetic variability influences drug response. PGx testing can improve patient care through personalized medication adjustments for a variety of conditions, including pain, mental health, cardiology, and oncology. Guest Authors: Lauren Jackson, PharmD, MPH and Jacob Marler, PharmD, BCCCP Music by Good Talk
I hope everyone's been enjoying recent holidays and the weather. It's finally feeling like spring here in NY! Today I am so excited to talk with my guest about becoming our own advocates in healthcare, and in what we are prescribed as part of that journey. We will be talking about pharmacogenomics as the tool that will help us usher in the future where safety comes first. Today's guest, Mark A. Smith began his career as a Special Agent with the FBI working on organized and white-collar crime. Followed by a Human Resources path from Pfizer, to PepsiCo, and ending as CHRO with Blockbuster Entertainment. Following an acquisition Mark returned to Western New York where he became actively involved in Children's Behavioral Health at both the state and national level. Mark's passion is focused on the clinical and economic value of Pharmacogenomics (PGx), and has placed him in the center of the national drive to “Standard of Care” for PGx. His network in autism, genetics, rare conditions, healthcare systems and payers positions him as an influential individual in the “fixing” of the American healthcare system. Connect with Mark via: Email: mark.smith@avalonbhs.com Website: avalonpgx.com, ismyrxsafe.com YT: @IsMyRxSAFE333 Linked In: Mark Smith
Join us as we welcome Dr. Emma Magavern to The Genetics Podcast! In addition to being a medical doctor with an English Literature degree, Dr. Magovern is a Clinical Research Fellow at the Centre of Clinical Pharmacology and Precision Medicine at Queen Mary, Barts, and the London School of Medicine and Dentistry. Emma also works closely with East London Genes and Health, a program dedicated to increasing engagement in a community that is underrepresented in research. Most recently, she published a paper looking at pharmacogenomics in a British South Asian population. Tune in to this interesting episode!
I hope everyone's been enjoying recent holidays and the weather. It's finally feeling like spring here in NY! Today I am so excited to talk with my guest about becoming our own advocates in healthcare, and in what we are prescribed as part of that journey. We will be talking about pharmacogenomics as the tool that will help us usher in the future where safety comes first. Today's guest, Mark A. Smith began his career as a Special Agent with the FBI working on organized and white-collar crime. Followed by a Human Resources path from Pfizer, to PepsiCo, and ending as CHRO with Blockbuster Entertainment. Following an acquisition Mark returned to Western New York where he became actively involved in Children's Behavioral Health at both the state and national level. Mark's passion is focused on the clinical and economic value of Pharmacogenomics (PGx), and has placed him in the center of the national drive to “Standard of Care” for PGx. His network in autism, genetics, rare conditions, healthcare systems and payers positions him as an influential individual in the “fixing” of the American healthcare system. Connect with Mark via: Email: mark.smith@avalonbhs.com Website: avalonpgx.com, ismyrxsafe.com YT: @IsMyRxSAFE333 Linked In: Mark Smith Visit https://marinabuksov.com for more holistic content. Music from https://www.purple-planet.com. Disclaimer: Statements herein have not been evaluated by the Food and Drug Administration. Products listed are not intended to diagnose, treat, cure, or prevent any diseases.
Episode Summary: In recognition of National DNA Day, April 25, 2024, Dr. Mary Weissman, Miss Courtney Harmon, and Dr. Becky Winslow discuss clinical pharmacogenomics resources, what pharmacogenomics information they provide, and how to navigate and utilize the pharmacogenomics information to answer a prescriber's clinical question about pharmacogenomics' relationship to an adverse drug event. Listeners interested in learning a step-wise approach to using the Food and Drug Administration's (FDA's) Table of Pharmacogenetics Associations and the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling, the Clinical Pharmacogenetics Implementation Consortium's (CPIC's) database, and the Pharmacogenomics Knowledgebase (PharmGKB) to demystify pharmacogenomics' role in adverse drug events will not want to miss this Precision Health and PGx Podcast episode. Biographies: Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over ten years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry to reduce barriers holding pharmacogenomics back from becoming a standard of care including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Acutis Diagnostics, Kentucky Teachers' Retirement System, and GenXys. A sought-after pharmacogenomics subject matter expert, Dr. Winslow, is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders. Dr. Mary Weissman is a pharmacogenomics science, clinical utility and reimbursement expert and inGENEious RX Incorporated team member. After earning her PharmD from the Arnold and Marie Schwartz College of Pharmacy, Dr. Weissman completed a two-year pharmacogenomics fellowship with a clinical diagnostic lab. Upon completing her academic training in pharmacology and pharmacogenomics, Dr. Weissman embarked on a journey to apply her expertise in clinical diagnostic laboratories and has held several key scientific and clinical roles in pharmacogenomics laboratories. Through informative presentations, training sessions, papers, and webinars, she has helped clarify pharmacogenomics' complexities and highlight its potential to revolutionize medication management strategies for pharmacogenomics' stakeholders. Miss Courtney Harmon is graduating from Manchester University's Pharmacy and Pharmacogenomics programs in 2024. She serves as a P4 liaison for Manchester University's chapter of Industry Pharmacists Organization (IPhO) and she is interested in pursuing a career in industry pharmacy. She has worked for Walgreens pharmacy for the last eight years. References: 1. Table of pharmacogenomic biomarkers in drug labeling. U.S. Food and Drug Administration. Published August 10, 2023. Accessed February 1, 2024. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling 2. Table of pharmacogenetic associations. U.S. Food and Drug Administration. Published October 26, 2022. Accessed February 1, 2024. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations 3. CPIC. Cpicpgx.org. Accessed February 1, 2024. https://cpicpgx.org 4. PharmGKB. PharmGKB. Accessed February 1, 2024. https://www.pharmgkb.org Keywords: #pharmacogenomics #ingeneiousrx #PGx #pharmacists #precisionhealthandpgxpodcast #pharmacypodcastnetwork #pharmacogenetics #genetics #sources #resources #FDA #CPIC #PharmGKB
In this episode of Hope Natural Health, Dr. Erin speaks with Whitney Prude about nutrition and meal planning. Whitney Prude is a practicing Board Certified Clinical Pharmacist (PharmD, BCPS), as well as a Mayo Clinic Certified Wellness Coach and Nationally Certified Health and Wellness Coach (NBC-HWC). Whitney is also certified in Medication Therapy Management and Pharmacogenomics. She currently works part-time as an inpatient clinical pharmacist at Mayo Clinic in Rochester, Minnesota where she has been for 7 years. She is a public speaker, entrepreneur, and CEO of Whole & Happy Living where she helps individuals truly transform their health from the inside out while also losing weight in a way that can be maintained long-term. During this episode you will learn about: Whitney's 5 Step Power Plan to Whole Health Transformation Why women can't seem to lose weight even after multiple diets Whitney's best advice for those who want to make a change Social Media - LinkedIn: https://www.linkedin.com/in/whitneyprude FB: https://www.facebook.com/mywholeandhappylife/ IG: https://www.instagram.com/mywholeandhappylife/ Website - https://www.mywholeandhappylife.com/ For more info on Whitney's program - https://learn.mywholeandhappylife.com/whole--happy-living-9574 Link to Testing: https://hopenaturalhealth.wellproz.com/ Link to Period Planner: https://www.amazon.com/dp/B0BBYBRT5Q?ref_=pe_3052080_397514860 For more on Dr. Erin and Hope Natural Health: Check out my Hormone Balancing Program: https://hopenaturalhealth.practicebetter.io/#/619ef36b398033103c7b6bf9/bookings?p=633b5cca8019b9e8d6c3518d&step=package Dr. Erin on Instagram: https://www.instagram.com/dr.erinellis/ Dr. Erin's Website: https://hopenaturalhealth.com/ Hope Natural Health on YouTube: https://www.youtube.com/channel/UChHYVmNEu5tKu91EATHhEiA Follow Hope Natural Health on Facebook: https://www.facebook.com/hopenaturalhealth naturopathichealth #hormonebalancing #period #periodreset #periodhelp #healthtransformation #weightloss #nutrition #mealplanning #wellnesscoach
Episode Summary: In recognition of National DNA Day, April 25, 2024, Dr. Mary Weissman, Miss Courtney Harmon, and Dr. Becky Winslow discuss clinical pharmacogenomics resources, what pharmacogenomics information they provide, and how to navigate and utilize the pharmacogenomics information to answer a prescriber's clinical question about pharmacogenomics' relationship to an adverse drug event. Listeners interested in learning a step-wise approach to using the Food and Drug Administration's (FDA's) Table of Pharmacogenetics Associations and the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling, the Clinical Pharmacogenetics Implementation Consortium's (CPIC's) database, and the Pharmacogenomics Knowledgebase (PharmGKB) to demystify pharmacogenomics' role in adverse drug events will not want to miss this Precision Health and PGx Podcast episode. Biographies: Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over ten years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry to reduce barriers holding pharmacogenomics back from becoming a standard of care including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Acutis Diagnostics, Kentucky Teachers' Retirement System, and GenXys. A sought-after pharmacogenomics subject matter expert, Dr. Winslow, is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders. Dr. Mary Weissman is a pharmacogenomics science, clinical utility and reimbursement expert and inGENEious RX Incorporated team member. After earning her PharmD from the Arnold and Marie Schwartz College of Pharmacy, Dr. Weissman completed a two-year pharmacogenomics fellowship with a clinical diagnostic lab. Upon completing her academic training in pharmacology and pharmacogenomics, Dr. Weissman embarked on a journey to apply her expertise in clinical diagnostic laboratories and has held several key scientific and clinical roles in pharmacogenomics laboratories. Through informative presentations, training sessions, papers, and webinars, she has helped clarify pharmacogenomics' complexities and highlight its potential to revolutionize medication management strategies for pharmacogenomics' stakeholders. Miss Courtney Harmon is graduating from Manchester University's Pharmacy and Pharmacogenomics programs in 2024. She serves as a P4 liaison for Manchester University's chapter of Industry Pharmacists Organization (IPhO) and she is interested in pursuing a career in industry pharmacy. She has worked for Walgreens pharmacy for the last eight years. References: 1. Table of pharmacogenomic biomarkers in drug labeling. U.S. Food and Drug Administration. Published August 10, 2023. Accessed February 1, 2024. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling 2. Table of pharmacogenetic associations. U.S. Food and Drug Administration. Published October 26, 2022. Accessed February 1, 2024. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations 3. CPIC. Cpicpgx.org. Accessed February 1, 2024. https://cpicpgx.org 4. PharmGKB. PharmGKB. Accessed February 1, 2024. https://www.pharmgkb.org Keywords: #pharmacogenomics #ingeneiousrx #PGx #pharmacists #precisionhealthandpgxpodcast #pharmacypodcastnetwork #pharmacogenetics #genetics #sources #resources #FDA #CPIC #PharmGKB
Join us this week on "This Week in Pharmacy" presented by the Pharmacy Podcast Network, for a groundbreaking live show that shines a spotlight on two critical and timely health topics. We're celebrating National Nutrition Month and National Endometriosis Awareness Month with not one, but two phenomenal women who are making waves in the world of pharmacy and beyond. Tune in as Dr. Tamar Lawful, the esteemed host of "Pivoting Pharmacy with Nutrigenomics," delves into the fascinating world of Nutrigenomics and its pivotal role in personalized nutrition and health. Discover how understanding your genetic makeup can revolutionize your approach to diet and wellness. Dr. Tamar Lawful, one of the 50 Influential Pharmacy Leaders of 2023, stands as a dedicated Integrative & Holistic Health Pharmacist with a special focus using nutrigenomics as a tool to empower women to prioritize their health, counteract chronic illness and reduce medication reliance. She completed her Doctor of Pharmacy from the University of the Sciences - Philadelphia College of Pharmacy, earning licenses to practice in California, New Jersey, and Pennsylvania. Her professional depth is evidenced by certifications in Nutritional Genomics, Pharmacogenomics, Ketogenic Nutrition, and Integrative Nutrition. As an Advanced Practice Pharmacist, she has developed a holistic healthcare model combining nutrition, genomics, and pharmacy. This led to the foundation of her company, LYFE Balance, Incorporated. In the same empowering episode, we're honored to feature Dr. Anne Arvizu, the visionary behind the "CorePreneur Podcast." Dr. Arvizu will shed light on the often misunderstood and under-discussed condition of Endometriosis, offering hope, insight, and support to those affected during National Endometriosis Awareness Month. The emerging link between endometriosis and some cancers, such as endometrial/uterine or ovarian. https://www.ncbi.nlm.nih.gov › articles › PMC9673303 Endometriosis shouldn't happen later in life but it does. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151055/ Charity: Please help with research opportunities and in creating awareness for endometrial cancer and prevention education. https://endometrialcancerfoundation.org Mental Health & Other Resources or to connect with Anne: For mental health resources, if you have experienced depression or anxiety due to chronic illness, endometriosis or cancer, you can download free mental health resources, on crisis mitigation and find professional coaching. https://annearvizu.com Anne's social links all here: https://bio.site/AnneArvizu https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673303/#:~:text=Endometriosis%20can%20increase%20the%20risk,screening%20in%20long%2Dterm%20management. Join us live for this special episode, brought to you by the Pharmacy Podcast Network, as we explore the cutting-edge of health with Dr. Tamar Lawful and Dr. Anne Arvizu. Together, let's empower our health and our lives.
In 2023, Insilico Medicine—a biotech company developing medications with a heavy reliance on AI—used AI to develop an experimental drug for the incurable lung disease idiopathic pulmonary fibrosis. The treatment is in mid-stage trials in the US and China, with some results expected in early 2025. Biotech is one of the fields that has been using generative AI for years, even before ChatGPT brought the technology to public view. Latest technology is essential in drug development. However, the convergence of digital health and pharma seems less clear. Digital health apps started gaining popularity around 2015, and at that time, it seemed all pharma companies were trying to figure out what they could gain from apps, so they financed accelerators and incubators one after the other. We've seen many ideas about how Pharma should or could use digital health. In the last few years, there have been many notorious cases when partnerships failed—a seemingly unicorn, Proteus, which designed digital sensors-equipped pills, went bankrupt in 2019 after Otsuka Pharmaceuticals pulled out of a funding round. Pear Therapeutics, the guiding star in the DTx space and the leader in FDA-cleared prescription digital therapeutics, partnered with Novartis, but in the end, the company filed for bankruptcy in 2023. So where is Pharma in relation to digital health and digital therapeutics? In this episode, Amir Lahav shares his thoughts about the impact of AI on biotech, the state of decentralized clinical trials, and the potential of technology for improved drug development, clinical trials, and patient responses. Newsletter: https://fodh.substack.com/ www.facesofdigitalhealth.com Show notes: [00:02:00] The Convergence of Digital Health and Pharma Discussion on the role of digital health apps in pharmaceuticals. The rise and fall of pharma and tech company partnerships, with examples like Proteus and Peer Therapeutics. [00:06:00] AI Trends in Biotech and Pharma [00:08:00] Enhancing Clinical Trials with AI and continuous patient monitoring [00:10:00] The Importance of Data in Clinical Trials [00:12:00] The Reality of Oncology Trials and Endpoints [00:14:00] Quality of Life in Medicine as the Endpoint [00:16:00] The Rise of Decentralized Clinical Trials [00:18:00] Pharma's Evolving Digital Health Strategies [00:22:00] Impact on Digital Health Industry [00:24:00] Collaboration and Sharing Knowledge in the Pharma Industry [00:26:00] The need for long-term investment and strategic piloting of digital health solutions [00:28:00] What Inspires in Pharma and Biotech in Personalized Treatments [00:30:00] The State of Precision Medicine and Targeted Therapies [00:34:00] The Role of Pharmacogenomics [00:36:00] Anticipations for 2024 and Beyond
THE EMBC NETWORK featuring: ihealthradio and worldwide podcasts
Hurricane H is excited to introduce you to Whitney Prude, a highly skilled and accomplished professional in the field of healthcare and wellness. As a practicing Board Certified Clinical Pharmacist (PharmD, BCPS), Whitney brings a wealth of knowledge and expertise to her work. Not only is Whitney a Mayo Clinic Certified Wellness Coach and Nationally Certified Health and Wellness Coach (NBC-HWC), but she is also certified in Medication Therapy Management and Pharmacogenomics. Her dedication to improving the lives of others is evident through her seven years of service as an inpatient clinical pharmacist at Mayo Clinic in Rochester, Minnesota. But Whitney's passion extends beyond her role as a pharmacist. She is a dynamic public speaker, an entrepreneur, and the CEO of Whole & Happy Living. At Whole & Happy Living, Whitney empowers individuals to achieve true transformation in their health from the inside out. Her holistic approach focuses not only on weight loss but also on long-term maintenance. With Whitney's guidance, you can navigate the complexities of your health journey and discover a path that leads to both happiness and wellness. Through personalized coaching and evidence-based strategies, she equips you with the tools you need to make lasting changes. If you're ready to take control of your health and embark on a journey of transformation, then look no further. Join us as we delve into Whitney Prude's expertise and learn more about her mission to help individuals live whole and happy lives. Make sure to subscribe to our channel for more insightful content and stay tuned for upcoming videos with Whitney. Together, let's transform our health and happiness! #health #happiness #transformation #pharmacist #coach #CEO #WholeandHappyLiving #wellness #mindfulness #selfcare #inspiration #motivation #positivevibes #holistichealth #selflove #selfimprovement #lifestyle #nutrition #fitness #meditation #success#healingjourney #transformation #empowermentjourney #selfhealing #personaltransformation #selfgrowth #mentalhealthawareness #selfcarejourney #findingstrength #selfempowerment #selflovejourney #selfdiscovery #mentalwellness #mindbodyhealing #growthmindset #emotionalhealing #innerstrength #positivemindset #selfimprovement #selfhealingjourney https://info.mywholeandhappylife.com/info2023
THE EMBC NETWORK featuring: ihealthradio and worldwide podcasts
Hurricane H is excited to introduce you to Whitney Prude, a highly skilled and accomplished professional in the field of healthcare and wellness. As a practicing Board Certified Clinical Pharmacist (PharmD, BCPS), Whitney brings a wealth of knowledge and expertise to her work. Not only is Whitney a Mayo Clinic Certified Wellness Coach and Nationally Certified Health and Wellness Coach (NBC-HWC), but she is also certified in Medication Therapy Management and Pharmacogenomics. Her dedication to improving the lives of others is evident through her seven years of service as an inpatient clinical pharmacist at Mayo Clinic in Rochester, Minnesota. But Whitney's passion extends beyond her role as a pharmacist. She is a dynamic public speaker, an entrepreneur, and the CEO of Whole & Happy Living. At Whole & Happy Living, Whitney empowers individuals to achieve true transformation in their health from the inside out. Her holistic approach focuses not only on weight loss but also on long-term maintenance. With Whitney's guidance, you can navigate the complexities of your health journey and discover a path that leads to both happiness and wellness. Through personalized coaching and evidence-based strategies, she equips you with the tools you need to make lasting changes. If you're ready to take control of your health and embark on a journey of transformation, then look no further. Join us as we delve into Whitney Prude's expertise and learn more about her mission to help individuals live whole and happy lives. Make sure to subscribe to our channel for more insightful content and stay tuned for upcoming videos with Whitney. Together, let's transform our health and happiness! #health #happiness #transformation #pharmacist #coach #CEO #WholeandHappyLiving #wellness #mindfulness #selfcare #inspiration #motivation #positivevibes #holistichealth #selflove #selfimprovement #lifestyle #nutrition #fitness #meditation #success#healingjourney #transformation #empowermentjourney #selfhealing #personaltransformation #selfgrowth #mentalhealthawareness #selfcarejourney #findingstrength #selfempowerment #selflovejourney #selfdiscovery #mentalwellness #mindbodyhealing #growthmindset #emotionalhealing #innerstrength #positivemindset #selfimprovement #selfhealingjourney https://info.mywholeandhappylife.com/info2023
In this episode, Tamara and Scott delve into the dynamic realm of pharmacogenomics within the long-term care. Covering its advantageous impacts and supported by research demonstrating its value, we offer an insightful overview of the presence and significance of pharmacogenomics in long-term care. Dr. Scott Stewart: linkedin.com/in/scott-stewart-34973870 Dr. Tamara Ruggles: linkedin.com/in/tamara-ruggles-491882251 References: - Jokanovic N, Jamsen KM, Tan ECK, Dooley MJ, Kirkpatrick CM, Bell JS. Prevalence and Variability in Medications Contributing to Polypharmacy in Long-Term Care Facilities. Drugs Real World Outcomes. 2017;4(4):235-245. doi:10.1007/s40801-017-0121-x - Saldivar JS, Taylor D, Sugarman EA, et al. Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility. Pharmgenomics Pers Med. 2016;9:1-6. Published 2016 Jan 19. doi:10.2147/PGPM.S93480 - Kistler CE, Austin CA, Liu JJ, et al. The feasibility and potential of pharmacogenetics to reduce adverse drug events in nursing home residents. J Am Geriatr Soc. 2022;70(5):1573-1578. doi:10.1111/jgs.17679 - Hayashi M, Hamdy DA, Mahmoud SH. Applications for Pharmacogenomics in Pharmacy Practice: A Scoping Review. Res Social Adm Pharm. 2021. Epublication ahead of print. - Rodriguez-Escudero I, Cedeno JA, Rodriguez-Nazario I, et al. Assessment of the Clinical Utility of Pharmacogenetic Guidance in a Comprehensive Medication Management Service. J Am Coll Clin Pharm. 2020;3(6):1028–1037. - PGx in the Long-Term Care Environment. RxGenomix. Accessed January 30, 2024. https://rxgenomix.com/insight/pgx-in-the-long-term-care-environment/ Scott Stewart PharmD Tamara Ruggles PharmD BCGP
In this riveting episode of Joey Pinz Disciple Conversations, we dive deep into the connection between joy, love, and personal growth with Rebecca Whitman.
Becky Winslow, BS, PharmD Host and Pharmacogenomics Medical Science Liaison; Behnaz Sarrami, MS, PharmD, Host and Pharmacogenomics Medical Science Liaison; Thierry Dervieux, PharmD, PhD, Chief Scientific Officer at Prometheus Laboratories In this episode of the PGX for Pharmacists Podcast, Dr. Thierry Dervieux, Dr. Behnaz Sarrami, and I discuss Dr. Dervieux's career as a PharmD, PhD, and chief scientific officer who has designed a pharmacogenomics test prescribers may use to optimize biosimilars for autoimmune gastrointestinal diseases. Dr. Dervieux will illustrate to our audience pharmacogenomics' potential beyond Tier 1 and 2 genetic testing by describing the clinical validity and utility of his laboratory's suite of tests in the autoimmune gastrointestinal disease diagnosis and treatment market. Behnaz and I hope this episode will inspire pharmacists interested in pharmacogenomics to think beyond the boxed PGx test most laboratories offer when they think about PGx and consider all the biological systems in which genetics impacts drugs' efficacy and safety. Disclaimer: Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc. Becky Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of any other entity. Transcription: 1 00:00:06,190 --> 00:00:19,620 You're listening to the Pharmacy podcast Network in a world where one size fits all medications dominate the pharmaceutical industry. 2 00:00:20,079 --> 00:00:24,750 Precision medicine brings a ray of hope for those seeking customized health care. 3 00:00:25,350 --> 00:00:32,830 Pharmacists have a unique opportunity to help people in need of specialized testing to ensure medications work as intended. 4 00:00:33,540 --> 00:00:44,680 Welcome to PGX for pharmacists where we unravel the wonders of precision medicine and its potential to revolutionize the way we approach pharmacy care. 5 00:00:45,169 --> 00:00:52,790 Get ready to uncover the secrets behind pharmacogenomics and how it's transforming lives one genome at a time. 6 00:00:52,799 --> 00:00:53,189 Hello, 7 00:00:53,200 --> 00:00:53,950 everyone. 8 00:00:54,159 --> 00:00:55,080 I'm your host, 9 00:00:55,090 --> 00:00:56,389 Doctor Becky Winslow. 10 00:00:56,409 --> 00:01:09,860 And you're listening to the PGX for Pharmacist podcast that we magazine recognized in 2021 as the ninth most listened to genetics podcasts in the world on the PGX for Pharmacist podcast. 11 00:01:09,870 --> 00:01:16,690 We explore all things pharmacogenomics related and our mission is to educate and advocate for PGX. 12 00:01:16,769 --> 00:01:23,849 We accomplish this mission through exclusive interviews with highly qualified and well experienced pharmacogenomics. 13 00:01:23,860 --> 00:01:29,720 Industry leaders such as today's special guest and my name is Baas Sami, 14 00:01:29,730 --> 00:01:32,739 the co-host of PGX for Pharms podcast, 15 00:01:32,750 --> 00:01:33,860 Pharmacogenomics, 16 00:01:33,870 --> 00:01:36,819 medical science liaison and a mentor to pharmacist. 17 00:01:36,889 --> 00:01:40,239 Connect with us on linkedin and let's get a conversation going. 18 00:01:40,269 --> 00:01:46,720 We want to hear from you and how you're impacting pharmacogenomic stakeholders and what you have learned throughout your journey. 19 00:01:48,510 --> 00:01:49,010 Ok. 20 00:01:49,019 --> 00:01:50,819 So without any further ado, 21 00:01:50,839 --> 00:01:54,769 I'm extremely pleased to introduce to our audience. 22 00:01:54,919 --> 00:01:56,059 Doctor Theory Devo, 23 00:01:57,239 --> 00:02:01,129 the Chief Scientific Officer at Prometheus Laboratories, 24 00:02:01,139 --> 00:02:08,139 and Perme Prometheus Laboratories is a reference clinical laboratory that's focused on the diagnosis, 25 00:02:08,149 --> 00:02:13,330 prognosis and monitoring of immune mediated inflammatory diseases. 26 00:02:13,970 --> 00:02:14,229 So, 27 00:02:14,240 --> 00:02:14,649 thank you, 28 00:02:14,660 --> 00:02:17,759 Doctor De for joining us on the podcast. 29 00:02:17,770 --> 00:02:18,589 Today. 30 00:02:18,600 --> 00:02:23,190 I'm excited to share your and Prometheus's story with our audience. 31 00:02:23,649 --> 00:02:25,630 Um in particular, 32 00:02:25,639 --> 00:02:45,369 I'm excited about you sharing your career journey as a farm D phd and Chief scientific officer and designer of the Predictor PK AD A which is a precision guided dosing test for the optimization of Humira Remicade and their bio cylinders. 33 00:02:46,119 --> 00:02:46,449 So, 34 00:02:46,460 --> 00:03:04,220 one of Bana's and my main goals for this episode of the PGX for Pharmacist podcast is to expand our audience's notion of what a PGX test looks like and to inspire them to think bigger than the traditional box PGX test. 35 00:03:04,229 --> 00:03:08,020 Most of them or most of you are uh familiar with. 36 00:03:09,020 --> 00:03:09,429 So, 37 00:03:09,440 --> 00:03:22,179 Doctor D uh I'd like to start the podcast by having our guests um introduce themselves and elaborate on how you are a pharmacogenomics expert. 38 00:03:23,619 --> 00:03:23,800 Yeah, 39 00:03:23,809 --> 00:03:24,250 thank you, 40 00:03:24,259 --> 00:03:25,759 Becky for having me. 41 00:03:25,770 --> 00:03:26,850 Uh uh Yes. 42 00:03:26,860 --> 00:03:27,289 So I am a, 43 00:03:27,300 --> 00:03:30,820 I am a pharmacist uh with uh a family who is a, 44 00:03:30,830 --> 00:03:33,039 a doctorate in pharmacokinetics. 45 00:03:33,539 --> 00:03:44,520 Uh I completed my studies in France and I came as a postdoc uh fellow uh to work in the United States about 20 years ago to work on the pharmacogenomic of anti cancer agents, 46 00:03:44,929 --> 00:03:49,160 uh primarily uh six Maturin as well as methotrexate. 47 00:03:49,169 --> 00:03:50,550 After my post doc, 48 00:03:50,770 --> 00:03:52,960 uh I moved uh in industry for promet. 49 00:03:53,490 --> 00:04:01,429 So I have a large experience in uh uh the implementation of pharmacogenetics testing in immune mediated inflammatory disease. 50 00:04:01,509 --> 00:04:12,550 Our lab Rome was the first uh clinical laboratory in the United States to offer the fin uh metyl transfer genotyping as well as the thin metabolites. 51 00:04:12,559 --> 00:04:13,029 So, 52 00:04:13,050 --> 00:04:21,989 uh uh of uh of 70 publications in the field and uh I'm very uh very excited to have uh to be on the postcard with you uh uh today. 53 00:04:23,660 --> 00:04:24,220 All right. 54 00:04:24,230 --> 00:04:27,359 So thank you for qualifying yourself as an expert. 55 00:04:27,369 --> 00:04:27,619 So, 56 00:04:27,630 --> 00:04:32,839 let's jump right in and delve into your current PGX work. 57 00:04:32,850 --> 00:04:33,279 So, 58 00:04:33,489 --> 00:04:36,540 if you'll tell us um a little about Prometheus, 59 00:04:36,549 --> 00:04:38,000 specifically, 60 00:04:38,010 --> 00:04:40,350 what is Prometheus's mission? 61 00:04:40,359 --> 00:04:43,799 And how are you guys going about accomplishing your mission? 62 00:04:44,760 --> 00:04:44,980 Yeah, 63 00:04:44,989 --> 00:04:45,700 sure. 64 00:04:45,709 --> 00:04:47,459 Uh So Promet is a, 65 00:04:47,470 --> 00:04:52,790 is a reference uh clinical laboratory based in Southern California in San Diego. 66 00:04:53,230 --> 00:04:56,809 Uh The company has been there for uh over 25 years. 67 00:04:56,820 --> 00:05:03,950 We are uh specialize in the differential diagnosis of autoimmune G I disease uh disorders, 68 00:05:04,059 --> 00:05:06,019 uh gastrointestinal disorder, 69 00:05:06,230 --> 00:05:08,619 uh and inflammatory bowel disease. 70 00:05:08,980 --> 00:05:10,299 And over the years, 71 00:05:10,309 --> 00:05:16,600 we have developed a portfolio of a differentiated solution to facilitate the diagnosis, 72 00:05:16,609 --> 00:05:17,470 the prognosis, 73 00:05:17,480 --> 00:05:18,429 the monitoring, 74 00:05:18,660 --> 00:05:21,910 as well as therapy selection with pharmacogenetics testing, 75 00:05:21,920 --> 00:05:24,730 which we are offering to our clinical laboratory. 76 00:05:24,829 --> 00:05:26,350 And most importantly, 77 00:05:26,410 --> 00:05:27,299 uh recently, 78 00:05:27,309 --> 00:05:35,660 we are uh uh developing some uh uh testing solution with the credit topic care test to optimize treatment to uh biologics. 79 00:05:36,470 --> 00:05:37,130 Ok. 80 00:05:37,140 --> 00:05:37,329 Well, 81 00:05:37,339 --> 00:05:37,450 that, 82 00:05:37,459 --> 00:05:38,049 that's great. 83 00:05:38,059 --> 00:05:46,100 Can you also tell us uh about the Prois Library of Precision Medicine Tests for inflammatory bowel disease for patients? 84 00:05:46,109 --> 00:05:49,230 how they benefit medication therapy management. 85 00:05:49,239 --> 00:05:56,429 Stakeholders across the IB DS patients journey from diagnosis to treatment to disease, 86 00:05:56,440 --> 00:06:02,049 monitoring through remission and how they differ from other lab tests for IBD and his treatments. 87 00:06:02,709 --> 00:06:03,209 Yes. 88 00:06:03,220 --> 00:06:03,369 So, 89 00:06:03,380 --> 00:06:04,399 so we uh our, 90 00:06:04,410 --> 00:06:10,100 our clinical laboratory offers some uh highly specialized test to facilitate the, 91 00:06:10,109 --> 00:06:16,779 the diagnostic of uh to facilitate the differential diagnosis of uh uh inflammatory bowel disease. 92 00:06:16,790 --> 00:06:22,359 So we are following uh testing solution with uh serological testing, 93 00:06:22,529 --> 00:06:23,799 for example, 94 00:06:23,809 --> 00:06:38,410 uh uh piana as as as well as uh macro microbial uh uh antibodies that are present uh uh in Crohn's disease as well as uh over uh auto uh auto antibodies that are present in er colitis. 95 00:06:39,339 --> 00:06:43,684 These are conditions that are uh uh somewhat difficult to treat. 96 00:06:43,704 --> 00:06:49,994 Uh And uh we are uh uh offering those tests to uh help uh gastroenterologist. 97 00:06:50,015 --> 00:06:51,114 Uh uh first of all, 98 00:06:51,125 --> 00:07:03,434 to establish a differential diagnosis of IBD as compared to other uh condition typically uh uh irritable bowel syndrome as well as over gastrointestinal disorder. 99 00:07:03,445 --> 00:07:05,635 When the diagnostic is established, 100 00:07:05,910 --> 00:07:31,839 uh we offer uh testing to uh establish a prognosis where we're gonna in inform the clinician that the patient has a more aggressive uh disease that will require more aggressive treatment where uh we can uh provide the testing solution to initiate uh uh the most appropriate therapy for uh for the patient uh with uh a testing where we are uh basically uh you know, 101 00:07:31,850 --> 00:07:36,559 establish de determining some genotyping with the fit transferal genotyping. 102 00:07:36,570 --> 00:07:37,279 For example, 103 00:07:37,290 --> 00:07:40,250 where we can uh indicate that the patient is, 104 00:07:40,260 --> 00:07:45,079 is likely uh to present with a side effect to those medication. 105 00:07:45,399 --> 00:07:46,170 And once you know, 106 00:07:46,179 --> 00:07:47,799 the the treatment is initiative, 107 00:07:47,809 --> 00:08:16,089 we have a portfolio of solution uh to facilitate the monitoring of the disease of the inflammatory bowel disease as well as the dosing optimization with uh uh the answer test which uh measure blood level uh for uh uh monoclonal antibodies that are indicated in the treatment of IB start with starting with Infliximab Adalimumab as well as uh Tein and vidal. 108 00:08:16,980 --> 00:08:24,040 So we have a comprehensive portfolio to uh to surround the clinician with uh a variety of testing solution. 109 00:08:24,049 --> 00:08:30,250 With our goal being to improve the uh the outcome uh of patients with uh with diabetes. 110 00:08:30,260 --> 00:08:34,520 And I think that the pharmacist has a very important role to play from that perspective. 111 00:08:35,179 --> 00:08:36,039 So theory, 112 00:08:36,049 --> 00:08:40,239 could you elaborate for us more on the predictor test? 113 00:08:40,249 --> 00:08:42,758 Um especially since you designed that test, 114 00:08:42,768 --> 00:08:44,218 we'd really like to know, 115 00:08:44,489 --> 00:08:45,039 um you know, 116 00:08:45,049 --> 00:08:49,638 what did that take and what role does it play in your suite of testing? 117 00:08:51,049 --> 00:08:51,270 Yeah. 118 00:08:51,280 --> 00:08:51,890 Sure. 119 00:08:51,900 --> 00:08:52,510 So the, 120 00:08:52,520 --> 00:08:52,570 the, 121 00:08:52,580 --> 00:08:52,989 the, 122 00:08:53,000 --> 00:08:53,229 the, 123 00:08:53,239 --> 00:08:59,960 the predictor test is uh uh is uh is utilized when the patient is receiving treatment. 124 00:09:00,280 --> 00:09:18,190 It's been speci specifically designed to optimize uh biological uh uh disease modifiers such as Infliximab adalimumab that are co therapies in the treatment of inflammatory bowel disease as well as other immune uh mediated inflammatory. 125 00:09:18,200 --> 00:09:21,549 This is what the test does is to you connect the blood specimen, 126 00:09:22,229 --> 00:09:23,049 uh you know, 127 00:09:23,059 --> 00:09:24,750 with dosing information. 128 00:09:25,039 --> 00:09:41,989 And what we do is to uh uh provide guidance uh to clinician with uh respect of the best dose to give in order to achieve the best the level which is the most consistent with uh uh the disease control that needs to be achieved for the patient. 129 00:09:42,169 --> 00:09:43,729 Typically a vast majority, 130 00:09:43,739 --> 00:09:46,159 about two third of a third to two third, 131 00:09:46,169 --> 00:09:54,669 a third of patient uh tend to be uh uh unresponsive uh to this uh very expensive medication. 132 00:09:54,989 --> 00:09:57,960 Uh Not because they don't have the uh you know, 133 00:09:57,969 --> 00:09:59,289 typically because they have a, 134 00:09:59,299 --> 00:09:59,590 you know, 135 00:09:59,599 --> 00:10:05,599 pharmacokinetic uh suboptimal pharmacokinetic uh that makes them uh you know, 136 00:10:05,609 --> 00:10:09,440 unresponsive because uh not enough drug has been given. 137 00:10:09,450 --> 00:10:18,469 So what we do with a predictor test is to basically estimate the pa the pharmacokinetic uh parameter for the patient. 138 00:10:18,750 --> 00:10:24,729 And from then uh re report the best dose uh to give in order to achieve the, 139 00:10:24,760 --> 00:10:31,570 the level which is consistent with the uh the most uh uh effective disease control to be achieved for the patient. 140 00:10:32,169 --> 00:10:33,059 So we are offering, 141 00:10:33,070 --> 00:10:38,049 we have developed a test for the Infliximab as well as Adalimumab which is Humira, 142 00:10:38,909 --> 00:10:41,309 but these are antimony causes factor. 143 00:10:41,460 --> 00:10:49,549 And we are also developing the test for vidur as well as uh is that are widely used also in the treatment of, 144 00:10:49,559 --> 00:10:51,969 of uh inflammatory bubble disease. 145 00:10:51,979 --> 00:10:52,669 Wow, 146 00:10:52,679 --> 00:10:55,450 uh for MET is a suite of tests. 147 00:10:55,460 --> 00:11:00,940 Goes well beyond um the PGX testing that our audience is most familiar with, 148 00:11:01,299 --> 00:11:08,679 uh which typically only includes snips for cyp genes and some pharmacodynamic genes. 149 00:11:08,690 --> 00:11:31,424 This is really exciting um genes and biomarkers related to immunology are not commonly found in what I call the box PGX tests such as those uh made by large uh laboratory manufacturing companies um where the panel has a set number of genes and uh you know, 150 00:11:31,434 --> 00:11:36,054 it was developed by a larger laboratory for maybe smaller laboratories use. 151 00:11:36,729 --> 00:11:39,010 So my understanding, 152 00:11:39,020 --> 00:11:53,729 having talked with you extensively theory is that immunology has fewer PGX test available because it's actually more difficult say than oncology to research and develop tests. 153 00:11:53,739 --> 00:11:54,119 So, 154 00:11:54,130 --> 00:12:00,729 could you elaborate for our audience on the difficulties that are associated with immunology, 155 00:12:00,739 --> 00:12:05,830 research and developing tests uh for immunology versus say oncology? 156 00:12:06,330 --> 00:12:06,530 Yeah, 157 00:12:06,539 --> 00:12:07,049 sure. 158 00:12:07,059 --> 00:12:09,969 So in uh in immunology, 159 00:12:09,979 --> 00:12:11,590 as compared to oncology, 160 00:12:11,599 --> 00:12:17,169 there is no such a thing such as a somatic mutation where for example, 161 00:12:17,179 --> 00:12:18,429 you're gonna have a behalf, 162 00:12:18,440 --> 00:12:18,659 you know, 163 00:12:18,669 --> 00:12:20,349 that indicates that the patient, 164 00:12:20,679 --> 00:12:20,919 you know, 165 00:12:20,929 --> 00:12:25,239 is likely to benefit or not from some treatment in immunology. 166 00:12:25,250 --> 00:12:26,750 This is far more complicated, 167 00:12:26,760 --> 00:12:28,830 complicated for the reason, 168 00:12:29,239 --> 00:12:31,020 starting with uh the fact that, 169 00:12:31,030 --> 00:12:31,179 you know, 170 00:12:31,190 --> 00:12:36,219 the response to this uh medication uh are multifactorial. 171 00:12:36,260 --> 00:12:37,820 And the fact that uh you know, 172 00:12:37,830 --> 00:12:39,380 the mutation that uh the, 173 00:12:39,390 --> 00:12:39,619 the, 174 00:12:39,630 --> 00:12:45,190 the single nucleotide polymorphism in the GM line which uh uh you know, 175 00:12:45,200 --> 00:12:52,429 can potentially associate with uh with outcome uh uh uh uh a lo in advance, 176 00:12:52,440 --> 00:12:58,359 meaning that uh they're gonna have a weak association uh with a response to those medications. 177 00:12:58,369 --> 00:13:09,609 So there is a necessity in immunology to combine multiple genetic polymorphism together in order to achieve uh some uh performances characteristics that will make uh you know, 178 00:13:09,619 --> 00:13:09,859 the, 179 00:13:09,869 --> 00:13:10,380 the, 180 00:13:10,390 --> 00:13:10,520 the, 181 00:13:10,530 --> 00:13:13,219 the clinician uh you know, 182 00:13:13,419 --> 00:13:15,619 uh order the test and most importantly, 183 00:13:15,630 --> 00:13:15,840 the, 184 00:13:15,849 --> 00:13:16,179 the, 185 00:13:16,190 --> 00:13:17,739 the payer to pay for the test. 186 00:13:17,750 --> 00:13:20,469 So this field has been uh you know, 187 00:13:20,479 --> 00:13:20,679 is, 188 00:13:20,690 --> 00:13:21,705 is moving for, 189 00:13:21,715 --> 00:13:21,994 you know, 190 00:13:22,005 --> 00:13:24,575 there are some tests that are being developed right now. 191 00:13:24,924 --> 00:13:39,034 But the biggest challenge is to be able to achieve again the the threshold of uh of performance that makes the test is variable enough uh to be uh again ordered by the clinician and the utilize uh to the benefit of the patient. 192 00:13:39,659 --> 00:13:41,200 I couldn't agree with you more. 193 00:13:41,210 --> 00:13:53,489 Um I've worked on the payer side or market access side of pharmacogenomics and even uh with a box test for which there's um a lot of research data available, 194 00:13:53,500 --> 00:13:55,119 even with those, 195 00:13:55,130 --> 00:13:59,760 it's sometimes difficult uh to get payers um to see the value. 196 00:13:59,770 --> 00:14:01,640 So I absolutely agree with you. 197 00:14:01,940 --> 00:14:03,679 Um The fact that you guys are, 198 00:14:03,690 --> 00:14:11,789 are uh investing in producing the data necessary says a lot about your laboratory. 199 00:14:11,979 --> 00:14:12,559 Um you know, 200 00:14:12,570 --> 00:14:15,380 and how committed you are to this testing and, 201 00:14:15,390 --> 00:14:17,320 and how you believe in the testing. 202 00:14:18,039 --> 00:14:23,640 So I just want to make sure that our audience recognizes that, 203 00:14:24,359 --> 00:14:24,619 you know, 204 00:14:24,630 --> 00:14:31,820 Prometheus doesn't simply provide tests to determine if drugs for IBD will be effective and safe. 205 00:14:32,190 --> 00:14:36,900 Um And maybe what the dose of the drug should be for the patient, 206 00:14:36,909 --> 00:14:40,219 but you have that whole suite of tests. 207 00:14:40,229 --> 00:14:47,380 Um the diagnostic test for the differential diagnosis all the way through remission. 208 00:14:48,030 --> 00:14:53,390 So can you elaborate you elaborated on it some in the previous question? 209 00:14:53,400 --> 00:15:01,229 But um can you tell us the difference between how you had to actually develop the test? 210 00:15:01,520 --> 00:15:02,530 Um You didn't, 211 00:15:02,539 --> 00:15:03,059 in other words, 212 00:15:03,070 --> 00:15:10,659 purchase a test from another manufacturer with the biomarkers that you include in your testing. 213 00:15:10,669 --> 00:15:16,830 Can you elaborate on how much more difficult it is to to develop a test from scratch? 214 00:15:18,169 --> 00:15:18,320 Yeah, 215 00:15:18,330 --> 00:15:18,659 sure. 216 00:15:18,669 --> 00:15:18,809 I mean, 217 00:15:18,820 --> 00:15:22,070 this is this is challenging for multiple and first of all, 218 00:15:22,080 --> 00:15:23,130 you need to have the, 219 00:15:23,419 --> 00:15:27,450 you need to have a clinical data set available with specimen available. 220 00:15:27,460 --> 00:15:28,159 Uh you know, 221 00:15:28,169 --> 00:15:28,780 in front, 222 00:15:28,859 --> 00:15:29,770 obviously, 223 00:15:29,859 --> 00:15:30,890 available. 224 00:15:31,200 --> 00:15:35,890 Uh So we are leveraging a pro meters a large bi bank of specimen. 225 00:15:36,299 --> 00:15:37,190 Uh as I said, 226 00:15:37,200 --> 00:15:39,719 Prometheus has been founded 25 years ago. 227 00:15:39,729 --> 00:15:40,599 So over the, 228 00:15:40,760 --> 00:15:41,919 the past two decades, 229 00:15:41,929 --> 00:15:54,849 we have been able to assemble a large uh substrate of data and specimen which we are uh uh using to uh uh establish our proof of concept if you will. 230 00:15:54,859 --> 00:16:07,559 And then when we have uh identify some genetic polymorphism that are uh adequately uh associated with uh uh disease outcome and disease progression as well as uh toxicity. 231 00:16:07,969 --> 00:16:11,469 Then we are entering validation phase where we are uh you know, 232 00:16:11,570 --> 00:16:14,789 using validation cohorts where we are again, 233 00:16:14,969 --> 00:16:22,630 combining multiple modalities together uh patient demographic as well as genetic marker together with theological marker. 234 00:16:22,640 --> 00:16:23,190 Actually, 235 00:16:23,500 --> 00:16:27,419 to come up with some Multivariate models that are uh again, 236 00:16:27,429 --> 00:16:39,250 bringing the performances characteristics of the pharmacogenomic test or its combination with our marker to the level where it's supposed to be in the first place to meet uh uh payer. 237 00:16:39,650 --> 00:16:41,190 And uh obviously, 238 00:16:41,200 --> 00:16:41,760 again, 239 00:16:41,770 --> 00:16:45,320 the patient uh to the benefit of the patient and to, 240 00:16:45,330 --> 00:16:46,619 to improve its outcome, 241 00:16:46,739 --> 00:16:47,429 the outcome. 242 00:16:48,340 --> 00:16:53,380 I think what you're describing really is the future of pharmacogenomics. 243 00:16:53,390 --> 00:16:54,599 Um In other words, 244 00:16:54,609 --> 00:17:03,419 not singing out pharmacogenomics as you know the end all and be all in the treatment paradigm. 245 00:17:03,559 --> 00:17:08,040 But using a PGX test in combination with, 246 00:17:08,050 --> 00:17:09,069 like you mentioned, 247 00:17:09,250 --> 00:17:11,160 other serological tests, 248 00:17:11,170 --> 00:17:12,959 maybe other genetic tests. 249 00:17:13,290 --> 00:17:14,890 Um But you know, 250 00:17:14,900 --> 00:17:25,869 I think what we want our audience to really wrap their heads around is that PGX is just a piece of that larger puzzle um from diagnosis to treatment to, 251 00:17:25,880 --> 00:17:26,910 to remission. 252 00:17:27,239 --> 00:17:29,880 So I think you guys are absolutely, 253 00:17:29,890 --> 00:17:31,579 you're already in the future. 254 00:17:31,589 --> 00:17:32,849 In other words, 255 00:17:32,859 --> 00:17:33,130 you know, 256 00:17:33,140 --> 00:17:39,689 you're already providing all these different uh tests um like you mentioned to, 257 00:17:39,699 --> 00:17:44,310 to facilitate from diagnosis to remission to remission. 258 00:17:44,660 --> 00:17:45,520 That's correct. 259 00:17:45,530 --> 00:17:45,829 Yeah. 260 00:17:46,349 --> 00:17:55,089 So um you've given us so much great information about uh the tests that that you guys offer. 261 00:17:55,329 --> 00:18:02,060 Can you explain to our audience um your newest test? 262 00:18:02,069 --> 00:18:03,859 Uh the responder test. 263 00:18:04,150 --> 00:18:12,979 And um what role it will play in the paradigm from the diagnosis of IBD to remission? 264 00:18:14,050 --> 00:18:14,260 Yeah, 265 00:18:14,270 --> 00:18:14,760 sure. 266 00:18:14,770 --> 00:18:15,569 So we, 267 00:18:15,579 --> 00:18:18,069 we are doing things a little bit different than other. 268 00:18:18,079 --> 00:18:19,489 We do believe that uh you know, 269 00:18:19,500 --> 00:18:21,449 the it has to be simple. 270 00:18:21,459 --> 00:18:24,189 Uh uh We can obviously construct some very, 271 00:18:24,199 --> 00:18:33,530 very complex algorithm and there are some tests that do that with a very sophisticated machine learning based tools that are available using neural networks, 272 00:18:33,540 --> 00:18:33,729 you know, 273 00:18:33,739 --> 00:18:34,790 those sorts of things. 274 00:18:34,800 --> 00:18:39,729 But we have taken on a different approach where with the responder test, 275 00:18:39,739 --> 00:18:40,329 we are basically, 276 00:18:40,339 --> 00:18:45,160 we are taking an approach which is very simple to address the first and foremost. 277 00:18:45,170 --> 00:18:53,020 Most important aspect of responding uh predicting response to uh to medication is the pharmacokinetics. 278 00:18:53,280 --> 00:19:03,250 Uh You cannot be responding to a drug if the drug is not given and you obviously cannot respond to a drug if the drug is not metabolized adequately. 279 00:19:03,359 --> 00:19:06,349 And this is what we are doing with the responder test. 280 00:19:06,579 --> 00:19:09,010 We are addressing some uh uh you know, 281 00:19:09,020 --> 00:19:11,630 fundamental issues with those uh biologist, 282 00:19:11,640 --> 00:19:12,410 for example, 283 00:19:12,660 --> 00:19:15,170 uh the anti tumor necrosis factors. 284 00:19:15,180 --> 00:19:15,650 So, 285 00:19:15,750 --> 00:19:19,199 such as uh Infliximab and Adalimumab, 286 00:19:19,209 --> 00:19:23,050 it is well known uh that uh uh those drugs, 287 00:19:23,060 --> 00:19:25,689 first of all are prone to immunization. 288 00:19:25,989 --> 00:19:36,949 Uh Meaning that uh uh the drug itself uh is recognized by the immune system uh and digested by the antigen presenting cells. 289 00:19:36,959 --> 00:19:42,209 If you will uh where you gonna have uh uh an immune uh uh response, 290 00:19:42,380 --> 00:19:56,979 uh mounted a cancer drug to produce uh immunogen that will severely impact its pharmacokinetics where the labels will be inadequate to produce uh the desired uh anti-inflammatory effects. 291 00:19:56,989 --> 00:19:57,150 So, 292 00:19:57,160 --> 00:19:58,890 we are with the risk conductors, 293 00:19:58,900 --> 00:20:01,040 we are combining two things together. 294 00:20:01,189 --> 00:20:07,959 First of all is the genetic test itself which uh predicts the risk of immun immunization. 295 00:20:07,969 --> 00:20:18,010 The name of the test is on HL A uh DQ A 105 ali uh that uh uh promotes the presentation of the, 296 00:20:18,020 --> 00:20:19,130 of the, 297 00:20:19,140 --> 00:20:19,910 of Infliximab, 298 00:20:20,010 --> 00:20:20,750 for example, 299 00:20:20,760 --> 00:20:32,130 to the T cell repertoire in order to uh promote the Ronon expansion and the formation of the anti antibodies together with uh another dimension which is the clearance, 300 00:20:32,140 --> 00:20:33,670 which is as important. 301 00:20:33,949 --> 00:20:36,209 Uh One of the key issue is the, 302 00:20:36,219 --> 00:20:36,770 the, 303 00:20:36,780 --> 00:20:41,239 the monoclonal antibodies and uh such as Infliximab or Adalimumab. 304 00:20:41,329 --> 00:20:42,280 But in fact, 305 00:20:42,290 --> 00:20:45,890 a neon antibodies that those drugs are uh you know, 306 00:20:45,900 --> 00:20:49,010 cleared and consumed uh from the, 307 00:20:49,020 --> 00:20:50,949 from the central compartment if you will, 308 00:20:50,959 --> 00:20:54,520 since we are doing a little bit of uh uh pharmacokinetics here. 309 00:20:54,530 --> 00:20:56,020 And uh uh you know, 310 00:20:56,030 --> 00:21:06,670 if the patient present who is uh a high degree of inflammatory burden is gonna have uh the patient will have a high clearance and that's gonna worsen uh in the, 311 00:21:06,680 --> 00:21:13,939 in the presence again of the HL AD Q A 105 genetic marker that uh associate with uh immunization. 312 00:21:13,949 --> 00:21:16,859 So I but this is a combination of both, 313 00:21:17,199 --> 00:21:19,359 these are the predictive factors of pharmacokinetic, 314 00:21:20,359 --> 00:21:38,209 which we combine together where the patient presenting with a risk of immunization as well as accelerated clearance due to the fact that the patient has high inflammation or due to the fact that they are so intrinsic pharmacokinetic properties that makes that the patient, 315 00:21:38,219 --> 00:21:38,300 you know, 316 00:21:38,310 --> 00:21:39,479 will clear the drug very, 317 00:21:39,489 --> 00:21:40,260 very fast. 318 00:21:40,560 --> 00:21:41,670 For example, 319 00:21:41,680 --> 00:21:46,819 due to the inefficient uh recirculation of the drug itself with the new, 320 00:21:46,869 --> 00:21:46,930 the, 321 00:21:46,939 --> 00:21:50,599 the the in the reticular on the system. 322 00:21:50,920 --> 00:21:51,619 Together, 323 00:21:51,630 --> 00:22:02,109 those patients presenting with uh uh together these uh poor prognostic factor of pharmacokinetic origin will tend to be severely underdose, 324 00:22:02,380 --> 00:22:06,719 will not be responding to the drug uh adequately as and they, 325 00:22:06,729 --> 00:22:10,719 and they probably should in the first place if you are able to address uh you know, 326 00:22:10,729 --> 00:22:12,270 the the the exposure. 327 00:22:12,439 --> 00:22:14,079 So what we do with this test, 328 00:22:14,089 --> 00:22:21,640 we will be able to inform uh the clinic that the patient is at risk of achieving, 329 00:22:21,650 --> 00:22:30,829 of achieving suboptimal pharmacokinetics and therefore being able to adjust the dose uh uh to start with more adequately. 330 00:22:30,839 --> 00:22:38,650 So that the the the proper uh exposure is achieved uh during induction to again to, 331 00:22:38,660 --> 00:22:39,040 to, 332 00:22:39,050 --> 00:22:39,380 to, 333 00:22:39,390 --> 00:22:40,890 to achieve a better outcome. 334 00:22:41,040 --> 00:22:47,270 And I think the pharmacist will have a very important role to play here in terms of absolutely, 335 00:22:47,280 --> 00:22:51,239 that information is priceless in the management of these medications. 336 00:22:51,250 --> 00:22:54,930 So thanks for elaborating on that. 337 00:22:56,010 --> 00:22:59,040 And if I may add in our previous conversation, 338 00:22:59,050 --> 00:23:00,810 uh before the recording of podcast, 339 00:23:00,819 --> 00:23:08,869 we had discussed um you guys' robust platform for collaborating with payers to obtain market access and reimbursements for the test. 340 00:23:09,109 --> 00:23:14,109 But without stealing the Thunder from uh Prometheus market access and reimbursement team, 341 00:23:14,199 --> 00:23:22,619 can you please uh briefly detail how Prometheus has proactively worked with payers to solve the problem. 342 00:23:22,920 --> 00:23:27,349 Um the population health problem by building the evidence payers want, 343 00:23:27,359 --> 00:23:41,170 want to see um about your test before you go to the market and then build the test and then hope the payers will see the value and the result and then that will improve the market access and reimbursement for your um precision medicine test. 344 00:23:42,160 --> 00:23:42,339 Yeah. 345 00:23:42,349 --> 00:23:43,180 So briefly I can, 346 00:23:43,189 --> 00:23:43,579 I'm, 347 00:23:43,589 --> 00:23:46,619 I'm probably not the right person to answer that question. 348 00:23:46,630 --> 00:23:47,369 We have a very, 349 00:23:47,380 --> 00:23:52,400 very efficient market access group uh uh pro meters that does a splendid job. 350 00:23:52,410 --> 00:23:59,780 But uh uh uh what I can tell you that we have an evidence uh uh development plan in place where we, 351 00:23:59,790 --> 00:24:14,000 we are establishing the clinical utility of our testing solution by demonstrating uh the payer value uh with respect of uh patient management and uh uh and the, 352 00:24:14,010 --> 00:24:16,630 and the impact of our technology on the, 353 00:24:16,640 --> 00:24:18,119 on physician behavior. 354 00:24:18,430 --> 00:24:21,319 Uh We have uh uh already uh you know, 355 00:24:21,329 --> 00:24:25,160 commercialized uh two of those tests for which we have initiated, 356 00:24:25,170 --> 00:24:29,040 initiated the Power studies uh that uh uh you know, 357 00:24:29,050 --> 00:24:32,000 already provide uh you know, 358 00:24:32,104 --> 00:24:34,484 differentiated and the value to, 359 00:24:34,494 --> 00:24:35,915 to the payer where we are, 360 00:24:35,925 --> 00:24:36,025 the, 361 00:24:36,035 --> 00:24:46,005 the clinicians are basically using our technology to make treatment decision uh as well as uh some prospective clinicality study which we are initiating, 362 00:24:46,145 --> 00:24:47,555 initiating to. 363 00:24:47,564 --> 00:24:48,574 Um uh again, 364 00:24:48,584 --> 00:24:49,425 demonstrate the, 365 00:24:49,435 --> 00:24:49,915 the, 366 00:24:49,925 --> 00:24:50,244 the, 367 00:24:50,255 --> 00:24:53,594 the payer value you uh uh we can certainly follow up with, 368 00:24:53,604 --> 00:24:58,755 uh you can certainly follow up with our market access group uh uh as appropriate there. 369 00:24:58,765 --> 00:25:00,765 Uh They can fill you with more information. 370 00:25:01,349 --> 00:25:01,589 No, 371 00:25:01,599 --> 00:25:02,520 that totally makes sense. 372 00:25:02,530 --> 00:25:03,310 That totally makes sense. 373 00:25:03,319 --> 00:25:10,890 But um we're excited that you're also farm d So how did you get to this role of outside the box path? 374 00:25:10,900 --> 00:25:11,550 There? 375 00:25:11,640 --> 00:25:17,530 There may be a pharmacist student or pharmacist wanting to switch or transition into a role such as yours, 376 00:25:17,540 --> 00:25:19,609 which is a Chief Scientific Officer. 377 00:25:19,619 --> 00:25:20,609 I want to learn more. 378 00:25:20,619 --> 00:25:23,920 So how would you um can you talk a little bit about that? 379 00:25:24,560 --> 00:25:24,780 Well, 380 00:25:24,790 --> 00:25:26,270 we are clinical laboratories. 381 00:25:26,280 --> 00:25:29,400 So in order to uh uh to be in my role, 382 00:25:29,410 --> 00:25:34,020 you need to have uh uh you need to have expertise in clinical laboratory science. 383 00:25:34,030 --> 00:25:36,140 So for the students is basically, 384 00:25:36,150 --> 00:25:36,300 you know, 385 00:25:36,310 --> 00:25:40,770 to do the family degree and then complete the family degree with uh a doctorate, 386 00:25:40,780 --> 00:25:40,930 you know, 387 00:25:40,939 --> 00:25:44,260 which is uh focus on clinical laboratory science. 388 00:25:44,270 --> 00:25:46,079 So you can achieve uh uh you know, 389 00:25:46,089 --> 00:25:47,640 the all the elements you need to be, 390 00:25:47,650 --> 00:25:48,219 for example, 391 00:25:48,229 --> 00:25:53,189 board certified uh as uh as as medical laboratory director. 392 00:25:53,199 --> 00:25:55,160 So you can uh uh so, 393 00:25:55,170 --> 00:25:55,589 uh yeah, 394 00:25:55,599 --> 00:25:56,030 this is, 395 00:25:56,040 --> 00:25:56,400 this is, 396 00:25:56,410 --> 00:25:57,209 this is uh you know, 397 00:25:57,219 --> 00:25:59,160 a great opportunity I think for pharmacies, 398 00:25:59,170 --> 00:26:10,800 there is an absolute need to uh have the clinical pharmacist provide uh uh drug information to healthcare professional as well as uh assist patient with the monitoring of their disease, 399 00:26:10,810 --> 00:26:15,229 the effectiveness of the therapy and um and uh you know, 400 00:26:15,239 --> 00:26:16,060 monitoring the, 401 00:26:16,069 --> 00:26:20,969 the side effect and the toxicity from uh from those uh those medication. 402 00:26:24,650 --> 00:26:24,959 Well, 403 00:26:24,969 --> 00:26:32,119 the I know our audience is going to have uh additional questions for you. 404 00:26:32,130 --> 00:26:32,540 I mean, 405 00:26:32,989 --> 00:26:35,609 you've provided them with so much great information, 406 00:26:35,619 --> 00:26:44,959 but it's only the beginning of what they could possibly learn um about um the testing that you do for IBD and, 407 00:26:44,969 --> 00:26:46,729 and even your career path. 408 00:26:47,050 --> 00:26:47,530 So, 409 00:26:47,540 --> 00:26:49,300 if you wouldn't mind telling us, 410 00:26:49,310 --> 00:26:51,359 um because we have to wrap up, 411 00:26:51,369 --> 00:26:52,670 unfortunately, 412 00:26:53,150 --> 00:26:55,810 this episode of the podcast, 413 00:26:55,819 --> 00:27:00,250 uh could you tell us how our audience members might be able to contact you directly. 414 00:27:01,260 --> 00:27:01,449 Yeah, 415 00:27:01,459 --> 00:27:07,079 I can be contacted on my uh on my email at TT W at como slab dot com. 416 00:27:07,949 --> 00:27:08,810 All right. 417 00:27:09,069 --> 00:27:09,300 Well, 418 00:27:09,310 --> 00:27:14,290 thank you again so much uh for joining us on this episode. 419 00:27:14,300 --> 00:27:15,290 We really, 420 00:27:15,300 --> 00:27:29,530 really hope that our listeners um ideas of not only what PGX can be but how PGX can be utilized in a comprehensive testing suite. 421 00:27:29,709 --> 00:27:35,670 We really hope that our a our audience will um listen in and learn this information. 422 00:27:36,280 --> 00:27:37,869 Um And to our audience, 423 00:27:37,880 --> 00:27:39,439 thank you for tuning in. 424 00:27:39,449 --> 00:27:42,619 We really hope that you've learned from this episode. 425 00:27:43,130 --> 00:27:46,339 Uh We do a whole lot of PG Xing here on this podcast. 426 00:27:46,349 --> 00:27:48,380 We talk about PGX Science, 427 00:27:48,390 --> 00:27:52,030 clinical application and the business of PGX. 428 00:27:52,260 --> 00:27:54,880 So we'd love to hear about from you. 429 00:27:55,099 --> 00:27:56,479 I love to hear from you. 430 00:27:56,489 --> 00:27:58,439 Um What can we teach you? 431 00:27:58,449 --> 00:28:00,920 What more can we teach you through our podcast? 432 00:28:00,930 --> 00:28:12,349 So please drop us a message on linkedin and let us know and please share this link to this podcast link episode with everyone so they can tune in and listen to the PGX for promises podcast. 433 00:28:12,520 --> 00:28:15,369 Leave us a review on Apple podcast or Spotify. 434 00:28:15,459 --> 00:28:18,130 And you can also visit us on PGX four, 435 00:28:18,140 --> 00:28:22,989 the number four Rx dot com to listen to all our other episodes. 436 00:28:23,000 --> 00:28:23,079 Well, 437 00:28:23,089 --> 00:28:23,790 thank you. 438 00:28:24,199 --> 00:28:28,750 Thanks for your interest in PGX and for spending some time with us. 439 00:28:28,760 --> 00:28:35,670 Please share this podcast and leave us a review on Apple podcasts or Spotify for all of our episodes. 440 00:28:35,680 --> 00:28:39,390 Please visit PGX four Rx dot com. 441 00:28:39,569 --> 00:28:43,380 That's PGX four Rx dot com.
Kashif Khan joins Dr. Stephanie to explore topics like longevity, cardiovascular health, weight management, and more. We highlight the value of combining genetic information with lifestyle factors for optimal health. Visit thednacompany.com/drstephanie for additional assistance and remember to consult with your primary healthcare provider for personalized advice.Episode Overview:0:02:31 Deep Dive into Genetics with Kashif Khan0:05:52 Understanding the Importance of Genetic Blueprint and Epigenetics0:09:01 Factors that Contribute to Aging0:17:20 The Role of Genetic Factors in Cardiovascular Health0:20:49 Gender Differences in Cardiovascular Health0:25:39 Prioritizing Action and Impact0:31:07 The Value and Potential Risks of NAC Supplements0:32:41 The Misunderstanding of Supplement Safety and Deaths0:37:28 Pharmacogenomics and the Impact on Medication Efficacy0:41:07 The link between glutathionization and autism0:49:35 European Supplements and Importing Knack0:52:53 The Truth about "Natural Flavor" in Food Processing0:56:12 The Overwhelming Total Load and Lack of DNA Evolution0:58:01 EMF Studies on Phone Safety and Brain Cancer Risk1:02:27 The Role of Dopamine and Serotonin in Food Choices1:07:41 Addressing the relationship between emotions and overeating1:11:35 The power of genetics and epigenetics in modifying lifestyleWe'd like to thank our sponsors:Athletic Greens – redeem an exclusive offer hereFourSigmatic Use code DRSTEPHANIE for 10% offOrion Red Light Therapy – Use the code STEPHANIE10 for 10% offSchinouusa – Use code DR.ESTIMA10 for 10% offBIOOPTIMIZERS – receive 10% off your order with Promo Code “ESTIMA”The DNA Company – $50 discount using code “DRSTEPHANIE” at checkout.HVMN Ketones – get 10% off your order with Promo Code “STEPHANIE”ILIA BeautyLiving Libations – Use code BETTER for 15% offLMNT Electrolytes – A FREE 7-flavor sample pack!PRIMEADINE – get 10% Off your Order with Promo Code “DRSTEPHANIE10”Follow Me On InstagramWatch Better! on YouTubeGet yourself a copy of my best-selling book, The Betty BodyJoin the Hello Betty Community hereSign up for my FREE MASTERCLASS: HEALTHY OFFERS – for health practitioners looking for strategies to earn more moneyAre you A Healthcare Practitioner? Join The Estima Certification Program Here
HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast
In this episode, we review the science behind genetic differences in humans in the CYP2D6 hepatic enzyme responsible for drug metabolism and how these genetic variants can lead to certain drugs being metabolized far too much or far too little, which can cause drug toxicities or a lack of effectiveness. Key Concepts About 20-25% of drugs on the market are metabolized by CYP2D6. Humans have a huge degree of variability in CYP2D6 metabolism ranging from “ultra” metabolizers to “poor” metabolizers. Drugs that heavily rely on CYP2D6 metabolism are prone to large variability in responses due to these genetic differences. Some drugs rely on metabolic inactivation of CYP2D6 whereas other drugs use the enzyme to become converted to a more active compound. Codeine and tramadol both heavily rely on CYP2D6 activation to a more potent opioid compound. Patients with excessive CYP2D6 activity will have toxicities (from too much of an active metabolite) whereas patients with low CYP2D6 activity will have little therapeutic effect. Numerous antidepressants (paroxetine, nearly all tricyclic antidepressants, and venlafaxine) rely on CYP2D6 metabolism. Differences in CYP2D6 metabolism have been shown to either cause toxicity or a lack of effectiveness with these medications. References Chartrand R, Forte AM, Hoger JD, Kane SP, Kisor DF. Pharmacogenomics and Commonly Prescribed Medications. AdvanCE. October 10, 2022. https://www.advancepharmacist.com/courses/pharmacogenomics-and-commonly-prescribed-medications. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13(1):116-124. doi:10.1111/cts.12692 Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants [published online ahead of print, 2023 Apr 9]. Clin Pharmacol Ther. 2023;10.1002/cpt.2903. doi:10.1002/cpt.2903 Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149
© 2020-2025 Ivy Podcast Discovery LLC
